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Abstract 
 
Glucose-6-phosphate dehydrogenase(G6PD) is an enzyme that catalyzes the conversion of 
glucose-6-phosphate to 6-phosphoglucolactone with the reduction of NADP+ to NADPH. It 
is the first component of the pentose phosphate pathway (PPP) that is a central and important 
biochemical pathway. The PPP functions to produce building block compounds and 
intermediates for energy production. The first three enzymes of the PPP are referred to as the 
oxidative phase and produce NADPH that is crucial for dealing with oxygen stress, 
especially in people with G6PD deficiency. 
 
There are tests for G6PD deficiency, but those used in the field are not reliable. The existing 
assays for G6PD use the NADPH it generates to reduce adye and produce a colour change, 
which can be observed with the naked eye and can be used to measure the kinetic parameters 
of the purified G6PD in the laboratory. Unfortunately, it suffers from a number of problems 
when used with crude preparations under field conditions. The equilibrium constant for the 
G6PD reaction is close to 1 so that the G6PD substrate will only be depleted if subsequent 
enzymes in the PPP are present. The extent of colour change will also depend upon the 
activity of the next two enzymes in the PPP and these may vary from person to person. The 
mutant forms of G6PD may be unstable, and may gives rise to false positive results during 
the assays. Hence, sensitive and reliable assays are needed. 
 
Here, we report an improvised colorimetric method for G6PD detection using tetrazolium 
salt, WST-8. The method used enzyme-coupling reaction of G6PD with another two 
downstream enzymes in the PPP. Addition of large excess of the two enzymes decreased the 
response time and increases the sensitivity of the test. Consequently, this enables detection 
of G6PD enzyme activity at low substrate concentrations compared with an assay of 
NADPH absorbance at 340 nm. The methods also generate NADPH eight times faster than 
reaction with G6PD alone. This makes the test more sensitive and predictive, which is also 
ideal for industrial applications.  
 
 vi 
We also extend the application of the colorimetric WST-8 assay for screening of 
recombinant libraries in a directed evolution study for improved stability. The screening 
protocols were modified to colony agar-blotting using filter paper as primary screening and 
96 well plates for secondary screening. The orange coloured formazans produced by the 
reaction, make it suitable and reliable for high-throughput qualitative and quantitative assays 
for dehydrogenases. With only four rounds of evolution, the method successfully identified 
promising variants with far improved thermal and chemical (urea) stability. 
 
Studies characterizing the properties and understanding the effect of mutations on variants 
are also discussed. The mutations responsible for improved stability were found located at 
the large structural NADP+ domain that is important for integrity and stability of the 
structure. The results also showed that the mutations brought changes in the oligomeric 
forms of G6PD. The thermostable variants were found to form higher order oligomers 
compared to the native enzyme. The correlation between enzyme stability and 
oligomerisation was also studied briefly. 
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1CHAPTER 1
Introduction
21.1 Preamble
This thesis is concerned with glucose-6-phosphate 
dehydrogenase (G6PD), an enzyme that sits at the 
junction of two central metabolic pathways: the 
glycolytic and pentose phosphate pathways. Glycolysis 
is used primarily for energy generation and utilizes 
nicotinamide adenine dinucleotide (NAD+) while the 
pentose phosphate pathway (PPP) is used for a variety 
of purposes, many of which depend upon the cofactor 
nicotinamide adenine dinucleotide hydrogen phosphate 
(NADPH). Clearly, the proper workings of the cell 
depend upon the activity and regulation of G6PD. 
Therefore, it is not surprising that G6PD figures 
prominently in the medical and biotechnology literature. 
However, the reaction catalyzed by G6PD is difficult to 
study, and the enzyme itself assumes a number of 
oligomeric states that further complicate its behavior. 
This chapter will give a brief review of G6PD properties 
and its place in cellular metabolism. This will be 
followed by a section dealing with the importance of G6PD, both in medicine and 
biotechnology. Finally, the specific aims of the project will be given.
1.2 The Enzyme: Glucose-6-phosphate dehydrogenase
As shown in Figure 1, G6PD catalyzes the oxidation of glucose-6-phosphate (G6P) into 6-
phosophoglucono-δ-lactone along with the simultaneous reduction of NADP+ to NADPH. 
Much of the work aimed at characterizing G6PD was done in the 1960s and 1970s and has 
been summarized in a review by Levy that was published in 1979.1 Although this review was 
published some time ago, it has the virtue of summarizing aspects of the enzyme that are not 
covered in detail in more recent reviews. Up-to-date reviews of the enzyme are also available 
and cover more recent developments.2, 3, 4, 5
Figure 1.1 The oxidative branch of 
the pentose phosphate pathway
31.2.1 Substrate Specificity
The G6PD enzyme acts with the greatest efficiency on glucose-6-phosphate (G6P), but it 
also has the tendency to oxidize a variety of related compounds, with varying specificity as 
described by Levy.1 G6PD from different organisms can have different coenzyme specificity 
as outlined in Table 1.1. The first three types are the most common, and only a few are 
known to belong to the last two groups. The work described in this thesis involves the 
enzyme from Escherichia coli that has a pronounced preference for NADP+/NADPH and it 
was only used to oxidize G6P (Type II) in the work described herein. 
Table 1.1 Classifications of glucose-6-phosphate dehydrogenase based on coenzyme 
    specificity
Type Classification of G6PD Example of microorganism
I NADP+ specific: do not react with NAD+ Candida utilis, Aspergillus 
niger, Bacillus cereus
II NADP+ preferring: react with NAD+ 
under non-physiological conditions
Rat, Human erythrocyte, 
Escherichia coli
III NAD+/NADP+ dual specific: react with 
both under physiological conditions
Leuconostoc mesenteroides, 
Pseudomonas aeroginosa, 
Arthrobacter 7C.
IV NAD+ preferring: react with both 
nucleotides but only react with NAD+ 
under physiological conditions
Pseudomonas fluorescens, 
Pseudomonas multivorans
V NAD+ specific: only react with NAD+ Acetobacter xylimum
1.2.2 Thermodynamics of G6PD reaction
The thermodynamics of the reaction catalyzed by G6PD are of some importance to the 
function of G6PD. The standard free energy change of the reaction catalyzed by G6PD 
depends on pH and other factors. The values reported in the literature have been reviewed by 
Levy.1 In summary, the standard Gibbs free energy for the forward reaction, as given in 
Figure 1.1, is a small positive value. The important point is that, under cellular conditions, 
the reaction catalyzed by G6PD is essentially reversible. However, the lactone product of the 
reaction is unstable and will spontaneously decompose in minutes. Therefore, characterizing 
this reversible reaction would be very difficult. In the cell, the second enzyme in the PPP 
pathway, 6-phosphoglucolactonase (6PGL), rapidly degrades the lactone. The 
thermodynamics of the reaction catalyzed by 6-phosphogluconate dehydrogenase (6PGD) 
4decarboxylases, the third enzyme in the PPP pathway, very much favors the formation of the 
product. These first three enzymes in the PPP constitute the oxidative branch of the pathway. 
The latter two enzymes of the oxidative branch ensure that the concentration of the lactone is 
always very low and that the reaction catalyzed by G6PD in the cell is, for practical 
purposes, irreversible. This would normally mean that the G6PD reaction would consume 
much of the G6P in the cell; however, under most conditions, this would be detrimental to 
the cell’s metabolism and it is not observed. Clearly, the G6PD activity must be regulated to 
take into account the cell’s needs.
1.2.3 The Regulation
A crucial factor in the regulation of G6PD is its inhibition by NADPH. Since the ratio of 
NADPH/NADP+ found in most cells is high and the concentration of lactone is very low so 
that the activity of G6PD in most resting cells is close to zero. In human erythrocytes, the 
intracellular concentration of the NADPH was estimated to be around 50 μM and about 40-
50 μM for NADP+.6 Since G6PD has a Km for NADP+ of 3-13 μM and a Ki of 9 μM for 
NADPH, the reaction would be inhibited under physiological conditions. Since the ratio of 
NADPH/NADP+ found in most cells is high and the concentration of lactone is low the 
activity of G6PD in most resting cells is close to zero. Under oxygen stress, when NADPH is 
consumed, G6PD decreases and is able to regenerate NADPH, thus ensuring the survival of 
the cell. In summary, the properties of the metabolites and enzymes of the PPP ensure that 
the pathway satisfies the needs of the cell – more will be said about this later. 
1.2.4 Structure and Function
Given the importance of G6PD, it is surprising that there were only three G6PD x-ray 
structures available in Protein Data Base (PDB, http://www.rscb.org/pdb/) at the time of 
writing. These structures were from a bacterium (Leuconostoc mesenteroides), yeast 
(Saccharomyces cerevisiae) and a mutant form of the human enzyme. As shown in the table 
below (Table 1.2), G6PD often exists in various oligomeric forms and this makes 
crystallization difficult. Both L. mesenteroides and S. cerevisiae G6PD exist as dimers, while 
the human enzyme exists as a dimer-tetramer mix. However, crystals were obtained from a 
mutant form of the enzyme that is predominantly a tetramer. Structures were determined for 
the native enzyme and in the presence of NADP+ and G6P.7, 8
5In most species, the G6PD monomer is composed of approximately 500 amino acids and 
have molecular weights in the range of 50-60 kDa (Table 1.2).9 In more primitive species 
like bacteria, the subunit is smaller. For example, L. mesenteroides contains 485 residues, 
whereas human G6PD consists 515 amino acids based on the cDNA sequence.10
Table 1.2 Comparative oligomeric state of G6PD
Source Average MW of 
monomer (kDa)
Dimer Tetramer Multimer
Bacteria 56.8 + + +
Lower Eukaryotes 54.7 + + -
Chlamydomonas 45.0 - + -
Plants 55.0 + + -
Drosophila 55.0 - + +
Mammals 61.3 + + +
Data obtained from Luzatto and Battistuzzi9
Approximately 52 G6PD sequences from over 40 different organisms were aligned with the 
human enzyme. It was noted that the sequence identity between the human enzyme and 
others was between 29% and 94%.11 The sequence identity between human and E. coli 
G6PD is about 30%. As indicated in Figure 1.2, nine conserved regions were found. These 
regions are critical for its function (Figure 1.3). 
Figure 1.2 Conserved regions in G6PD macroevolution. A linear representation of the G6PD protein 
shows the position of nine highly conserved peptides. The scale refers to amino acid numbering in 
human G6PD. Bold amino acids are conserved in all species mentioned. The K with an asterisk is 
the reactive lysine residue at position 205 in the human sequence.12
6As with many dehydrogenases, the G6PD subunits consist of two main domains. The smaller 
N-terminal domain is responsible for binding of cofactor used in catalysis (residues 31-200), 
while the large C-terminal domain is responsible for binding G6P (residues 201-515) as 
illustrated in Figure 1.3.7, 13 The N-terminal peptide folds into a α/β domain known as the 
Rossman fold, while the C-terminal peptide forms a α+β domain consisting nine parallel 
strands of β sheets that are unique to G6PD. The N and C-terminal domains are linked by a α 
helix. The C-terminal domain of human G6PD consists a regulatory NADP+ and a G6P 
binding sites, as determined by Au et al. (Figure 1.4).13 The regulatory NADP+ is bound 
close to the dimer interface formed by the residues close to the C-terminal and is some 
distance away from the catalytic and coenzyme binding sites as shown in Figure 1.3. 
Domain 2
G6P binding 
domain
G6P
NADP+
Domain 1
NADP+ binding
Figure 1.3 The monomeric structure of G6PD from L. mesenteroides (PDB: 1E7Y).7 The figure 
illustrates the two domains in G6PD enzymes. The structural NADP+ and the G6P are drawn in red 
and purple in sticks, respectively. The calcium ion is shown as a dark blue sphere.  
In human G6PD, the cofactor − NADP+ stabilizes the tetrameric form of the enzyme. Human 
G6PD contains two NADP+ binding sites: a catalytic site and a structural site. Many of the 
common mutations linked to impaired G6PD activity are located near the structural NADP+ 
site.13 This suggests that reduced activities are associated with altered enzyme regulation. 
Impairment of the NADP+ binding will also affect both stability and folding of the protein. 
As can be seen in the diagram below (Figure 1.4), the G6PD quaternary structure can be 
described as a dimer of dimers, i.e. there are tight contacts with one two-fold related 
7molecule and weak contacts with the other. Presumably, the tight dimers correspond to the 
less active dimers that exist in solution, while the tetrameric form corresponds to the active 
tetrameric form of the enzyme found in solution. 
Dimer interface
Tetramer 
interface
NADP+
Figure 1.4 Structure of human G6PD tetramer (PDB: 1QKI).13 The four monomeric subunits are 
represented in different colours. The structural NADP+ molecules are drawn in black sticks. 
A number of studies have established that the enzymatically active form of human G6PD is 
either dimeric or tetrameric14, 15 and the equilibrium between the two forms is affected by 
factors such as ionic strength, pH, and divalent cations.16, 17, 18 Dimers are favored at high 
pH, ionic strength and G6P concentrations, while tetramers are favored at low pH, ionic 
strength and the presence of some divalent cations like Mg2+ (Figure 1.5). Furthermore, the 
equilibrium between these forms can also be affected by incubating the enzyme with the 
G6P and NADPH; the presence of both compounds causes dimers to dissociate into inactive 
monomers.18, 19, 20 Conversely, incubating the monomer with the G6P and NADP+ can restore 
the dimeric state. Unlike the human enzyme, the oligomeric state of the E. coli enzyme has 
only been partially characterized; it is known to exist as an equilibrium mixture of many 
high molecular weight species − dimers and tetramers. 
8Tetramer
(active form)
Dimer
(active)
Monomer
(inactive)
High pH & ionic strength
Low pH &ionic strength,
Divalent cations
NADPH
NADPH, -SH
Figure 1.5 The equilibrium between the oligomeric forms of G6PD in vitro.
1.2.5 Kinetics Properties
For human enzyme, the reaction is an ordered and sequential reaction with NADP+ bound 
first and NADPH released last. The same results were also obtained for enzymes from L. 
mesenteroides.21, 22, 23, 24 Table 1.3 gives the kinetics constants obtained for the different 
forms of G6PD that have been characterized.
9Table 1.3 Kinetics properties of G6PD enzymes
G6PD source Form kcat (s-1) Km G6P (mM) Km NADP+ (mM) Reference
Human
Placenta 2’ mer 296 0.040 0.020 [25]
20-275 0.010-0.052 0.002-0.007 [26]
Bacteria
E. coli 174 0.174 0.008 [27]
87 0.1-0.145 0.015
Thermotoga Maritima 2’ mer 3500 0.15 0.03 [28]
Plants
Parsley leave 1’ mer 0.251 0.162 [29]
Spruce roots 73 6.6 [30]
Fungi
Aspergillus aculeatus 2’ mer 83 0.075 0.006 [31]
Others
Rainbow trout 1’ mer 0.5 0.166 [32]
Sheep kidney 0.041 0.0147 [33]
Details of the enzyme properties are available through the BRENDA database (http://www.brenda-enzymes.org/).
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The catalytic mechanism of G6PD, based on L. mesenteroides enzyme, involves key and 
highly conserved residues: Asp177 and His178 (corresponding to cofactor binding domain), 
and His240 (corresponding to substrate binding domain). As proposed by Cosgrove et al. 
(1998),34 the oxidation involves the general base that abstract the proton from C1-hydroxyl 
of G6PD, thereby allowing the transfer of the C1-hydride to the C4 position of the co-
enzyme (Figure 1.6). The aspartate residue (Asp177) is involved in the catalysis by stabilizing 
the positive charge on the adjacent histidine residue (His 240) in the transition state.7 The role 
of the aspartate residue is to alter the pKa of the histidine and position it so that it can 
abstract a proton from the substrate, as indicated in Figure 1.6.
Figure 1.6 Proposed catalytic mechanism of L. mesenteriodes G6PD. Showing the catalytic dyad of 
Asp 177 and His 240 abstracting the proton of G6PD and the reduction of the coenzyme. Figure 
adapted from Cosgrove et al. 34
1.3 Pentose Phosphate Pathway: Function and Regulation
The PPP was discovered in Warburg laboratory in the 1930s. The work with the G6PD 
enzymes from yeast and erythrocytes demonstrated the NAD+ and NADP+ act as an electron 
carrier for oxidation of G6P to 6-phosphogluconate.35, 36 Further studies followed to 
complete the pathway map as it is known today. A detailed description of the pathway can 
be found in most biochemistry texts, and only a brief description will be given here. The 
oxidative steps of the PPP are illustrated in Figure 1.1. The pathway is divided into two 
branches, known as the oxidative and non-oxidative branches.
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The oxidative branch starts with G6PD and has been described above. This branch of the 
pathway is used to generate NADPH for biosynthesis of fatty acids and steroids and as noted 
previously, to supply reducing equivalents for dealing with oxygen stress. Meanwhile, the 
non-oxidative section of the pathway utilizes transaldolase and transketolase enzymes to 
produce a variety of sugars that can be used in biosynthesis reactions while others are used to 
produce intermediates of the glycolytic pathway.37
Figure 1.7 Scheme of the Glycolysis and Pentose phosphate pathway. The two branches of the 
pathway are indicated by the different colour.
Abbreviations: G6PD, glucose-6-phosphate dehydrogenase; 6PGD, 6-phosphogluconate 
dehydrogenase; 6PGL, 6 phosphoglucolactonase; NADP+, NADPH, oxidized and reduced 
nicotinamide adenine dinucleotide phosphate. 
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1.4 The Importance of G6PD; the significance of this work
The work reported in this thesis is importance for three reasons. First, as explained below, 
the enzyme G6PD is of considerable medical importance and a sensitive method for 
detecting its activity would find many applications. Secondly, G6PD can be used to generate 
NADPH for reactions of interest to university researchers and biotechnologists; particularly 
in driving cytochrome P450 catalyzed reactions. Thirdly, there is a great deal of interest on 
how G6PD functions: in particular how it is regulated. It is thought that G6PD regulation 
involves changes in its oligomeric state, but there is little understanding of the molecular 
details of how these changes are brought about.  
The medical importance of G6PD rests primarily upon its role in dealing with oxidative 
stress, particularly in human red blood cells (erythrocytes). The NADPH generated by G6PD 
is used by enzymes involved in dealing with oxidative stress that can arise in malaria 
infections. Malaria is a mosquito-borne disease caused by a unicellular eukaryotic organism 
of the genus Plasmodium, with four species capable of infecting human: P. falciparum, P. 
vivax, P. ovale and P. malaria. A detailed description of Plasmodium life cycle can be found 
elsewhere38, 39 − for our purposes it is sufficient to know that in humans the Plasmodium first 
infects liver cells (hepatocytes) where they develop and multiply with the release of 
merozoites into the bloodstream where they infect and rupture erythrocytes. Most of the 
common drugs that treat malaria act against the parasite in the erythrocytes. The peptide 
chain of hemoglobin is degraded and used by the Plasmodium as a source of nutrition. The 
residual heme is problematic as it disrupts membranes and can be lethal to the parasite and 
can cause hemolytic anemia in the host. The parasite detoxifies the heme, in part by 
sequestering it into hemozoin (malaria pigment). The parasite also relies upon host process 
to degrade heme and these require NADPH that is only generated by the PPP. People with 
G6PD deficiency have a difficulty in degrading heme and under some conditions, this can 
lead to anemia caused by the disruption of erythrocyte membranes. However, the inability to 
efficiently dispose of heme confers a level of resistance to the malaria parasite. Given the 
widespread occurrence of malaria, it is not surprising that mutations that give rise to G6PD 
deficiency are more common than any other human enzyme.
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There are drugs to treat malaria but, they are not 
without side effects for people who have defects in 
their G6PD – there are over 400 million of these 
individuals concentrated in areas where malaria is 
common.40, 41 Individuals with variants forms of this 
enzyme can develop life threatening hemolytic 
anemia when treated with 8-aminoquinoline 
antimalarial drugs. Most antimalarial drugs, such as 
chloroquine, function by preventing the parasite from 
detoxifying the heme by converting it to hemozoin.42 
The drugs kill the parasite and heme spills into the 
erythrocyte where it is mopped up by the cell’s 
degradation systems. People with reduced levels of 
G6PD activity cannot deal with elevated levels of 
free heme and severe anemia (sometimes lethal) results. Primaquine (PQ), the only drug 
available for radical cure of P. vivax, has a short half-life in circulation and must be 
administered drugs daily for 14 days.42, 43, 44 Adherence to this cumbersome regimen is 
suboptimal and it is therefore not widely used in endemic countries. Early treatment 
termination will fail to remove all the liver stage parasites and commonly results in relapse. 
Tafequine (ClinicalTrials.gov Identifier: NCT01205178) is intended to deal with the 
problem of poor adherence, making an effective cure of P. vivax infection more feasible. It 
needs to be taken only once and it remains effective in-vivo for 2-3 weeks − long enough to 
deal with any parasite hiding in hepatocytes.45, 46 Both PQ and tafenoquine are active for 
liver stage P. vivax and have the potential to eliminate the disease by effectively clearing 
parasite reservoirs. The longer half-life of tafenoquine offers a major breakthrough in 
malaria control. However, it could be lethal for people with malaria who are G6PD deficient. 
Hence there is an urgent need for a reliable method to detect G6PD deficiency.
People with severe G6PD deficiency frequently suffer from debilitating anemia while under 
conditions of oxidative stress. However, this deficiency confers an advantage on those 
infected with the malaria parasite. The inability of these individuals to deal with high levels 
of heme is detrimental to the survival of the parasite and this deficiency is common in 
countries such as tropical and subtropical Asia where malaria is common. The nature of the 
deficiency varies across ethnics groups, but even within a single ethnic group, there are 
numerous mutations that can affect G6PD activity in different ways.13, 47, 48 In some cases the 
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catalytic properties of the enzyme are compromised, while in others the enzyme is not stable, 
resulting in insufficient G6PD activity. In a first world country, mutants could be detected by 
sequencing DNA, but malaria occurs mainly in remote communities that do not have ready 
access to the facilities for the tests. Thus, practical test, which is simple and robust for 
example, colorimetric enzyme assays, which detect the G6PD activity by colour changes, is 
critical.
The existing assays for G6PD use the NADPH it generates to reduce a dye and produce a 
colour change. This assay can be observed with the naked eye and can be used to measure 
the kinetic parameters of purified G6PD in the laboratory.49 Unfortunately, it suffers from a 
number of problems when used with the crude preparations under field conditions. The 
equilibrium constant for the G6PD reaction is close to 1 so that the G6PD substrate will only 
be depleted if subsequent enzymes in the PPP are present. The extent of colour change will 
also depend upon the activity of the next two enzymes in the PPP – and these may vary from 
person to person. There are also variable factors due to the G6PD itself. As already 
mentioned, the kinetics properties of mutant enzymes may cause problems. Specifically, 
elevated Km values may not be detected under the conditions of the assay since saturating 
levels of substrates are used. Thus, people with high-Km variants of G6PD could experience 
severe anemia during treatment with PQ.
There are other factors that could cause the assay to fail. The human enzyme is known to 
have two NADP+ binding sites − one catalytic and one regulatory.13 The regulatory site is 
located near a symmetry axis and probably functions by altering the oligomeric structure of 
the protein. The human protein exists as an equilibrium mixture of dimeric and tetrameric 
species – the tetrameric form being more active than the dimeric form.7, 13 Mutants with 
reduced affinity for the NADP+ at the regulatory site may have normal activity under the 
conditions of the assay, but fail under the conditions found in the cell where much lower 
NADP+ concentrations are present. The results of tests will depend upon the oligomeric state 
of the enzyme at the time a blood sample is taken  – they may vary from person to person.
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1.5 Classifications of G6PD deficiency variants: standard guidelines
It is widely known since the early 1960s that genetic variants of human G6PD are extensive. 
Over 400 variants have been listed and named according to their geographical distribution. 
Each of the variants possesses different biochemical properties. This makes the effort for 
identification and classification difficult. A world Health Organization (WHO) Scientific 
Group in 198950 has developed criteria for identification of G6PD variants. The criteria 
include the red blood cell G6PD activity, thermal stability, electrophoretic migration, and the 
Michaelis-Menten kinetics constant (Km) for the G6P. Based on these guidelines, the 
characterizations of the variants have been improved and enable the variants to be assigned 
into five different classes depending on the degree of enzyme deficiency and clinical 
manifestations (Table 1.4).
Table 1.4 Genotypic and phenotypic variation of human G6PD 
Class Clinical manifestations Example Electrophoretic 
mobility
Km G6P 
(μM)
I CNSHA c, d Barcelona Fast 40
II Severely deficient, 
AHAa; NNJb; 
<10% residual activity 
Mediterranean Normal 25
III Moderately deficient, 
AHAa; NNJb; 
10-60% residual activity
A- Fast 70
IV Normal activity; None; 
60-150% residual 
activity
A, B Fast, Normal 70
V Increased activity; None Hektoen Normal
Table was adapted from WHO (1989)50
aAcute hemolytic anemia from drugs, infections, and fava beans.
bNeonatal jaundice.
cChronic non-spherocytic hemolytic anemia.
dG6PD activity also very low (<5%) in granulocytes, with consequent increased susceptibility to 
certain bacterial infections.
Apart from malaria, there are other diseases that are problematic for people with G6PD 
deficiency. According to Siddiqui and Khan51, Mengel et al.,52 and McCaffrey et al.,53 
hepatitis A, pneumonia and typhoid fever are common bacterial and viral infections that 
cause hemolytic anemia for G6PD deficient patients. Favism is hemolytic anemia that arises 
because of ingestion of fava beans (Vicia faba), It can cause hemolysis in G6PD deficient 
patients in areas where fava beans are a part of the diet: the Middle East, North America, and 
mostly in Mediterranean countries.54 Ingestion of fava beans causes hemolysis in some 
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G6PD deficient individual; all patient with favism are G6PD deficient, but not all G6PD 
deficient patients are sensitive to the fava beans.55
1.6      G6PD Detection
1.6.1 Methods for identification of G6PD variants in laboratory
At present, there are various approaches at the molecular level to detect the G6PD variations; 
both direct and indirect detections of the genetic disorders. The most direct way is DNA 
sequencing and spectrophotometric assay. 
DNA sequencing is by far the most powerful and accurate detection method to analyze the 
mutations.56, 57 The genomic DNA sequence can be determined with gene specific primers 
that, are complementary to the genomic DNA. Although this method is powerful, it is not 
practical for field purposes due to costly instruments. Furthermore, it assumes that the 
sequences of all detrimental mutants are known; new or rare mutations may not be detected. 
Hence, a simple enzyme assay that detects activity is required. 
In spectrophotometric assays, the activity of the G6PD enzyme is measured based on the 
production of NADPH by the G6PD reaction, detected at UV range (340 nm). High 
concentration of substrate at saturation level is required to produce a detectable signal. There 
are a number of other laboratory methods available to screen for G6PD deficiency. The 
assays are conducted using simple tools as described in Table 1.5 below. The advantages as 
and the disadvantages for the detection of G6PD are given in Table 1.5.
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Table 1.5 Diagnosis and screening assays for G6PD deficiencies
Test Commentary Advantages/Pitfalls Reference
Definite assay
Spectrophotometry An enzymatic activity assay. The initial velocity of the 
reaction is measured as an increase in the absorbance 
at 340 nm 
Requires a lab with costly and 
sophisticated equipments. It uses 
substrates at saturation level.
[58]
Fluorescent spot test A screening test where a drop of blood is placed on 
filter paper and the reaction is incubated. The result is 
illuminated using UV lamp to determine the presence 
of fluorescence, which indicates the G6PD activity. 
Special equipment is not required. It 
only requires a UV lamp, water bath 
and micropipettes
Cheap, simple and reliable− It can be 
used on stored blood but only reliable 
for detection in patients with severe 
G6PD deficiency. Moderately reliable 
on heterozygous female,
[59, 60, 61]
Indirect assay
Tetrazolium staining 
test, MTT
Determination of G6PD activity using chromophores. 
The G6PD activity translated the NADPH produced 
into a colour product.
Prolonged incubation time required.
Fresh blood required.
False positive reported.
[62, 63]
Methemoglobin 
reduction methods 
Assessment of G6PD activity by examining the rate of 
NADPH reduction in the presence of redox catalyst
Requires a biochemistry laboratory. [64]
WST8/1-methoxy PMS An enzyme assay that uses tetrazolium salt WST-8 
and an electron carrier; PMS to determine the G6PD 
activity. The NADPH produced is indicated by the 
colour developed.
Rapid and simple.
Less light sensitive and compatible 
with usage of dried bloodspots.
Uses quite high concentration of 
substrates.
Suitable for field use.
[65, 66]
Rapid diagnostic test
BinaxNOW G6PD 
testTM 
A qualitative chromatographic enzyme test. Rapid and easy to use but costly.
Limited range of suitable temperature 
required to perform the test- work at 
18 – 25 °C (not suitable for malaria 
endemic region.
[67, 68]
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1.6.2 The pitfalls 
There is already good assay for G6PD. It involves using the NADPH generated by G6PD to 
reduce a dye and produce a significant colour change. This assay is sensitive and can be 
evaluated by eye. It is ideal and practical for measuring purified G6PD in laboratory scale. 
However, it suffers from a number of problems when using with the crude preparations 
(blood sample) in field tests. 
(I) It is not the basic principle of the assay that caused the low reliability, but the 
G6PD enzyme itself − it is a highly regulated enzyme that could vary in 
activation state from individual to individual − G6PD protein in human is known 
to exist in mixtures between tetramers and dimers − the tetrameric form being 
much more catalytic active than the dimeric form. Moreover, the mutant forms of 
G6PD that are observed in the field are normally those that have conferred an 
advantage to the individuals and are not devoid of the activity. Hence, the results 
of tests will depend upon the state of the enzyme at the time a blood is taken. The 
variation between variants may also affect the catalytic rate and give rises to false 
positive results. The G6PD activity measured from a mutant offers an ambiguous 
result that may lead to inappropriate administration of drugs and fatal 
consequences. To counter this, the assay must be calibrated to sensitively detect 
the relatively small differences in the activity of the G6PD. 
(II) In addition, mutant forms of G6PD are often defective in stability and give rise to 
a false reading.  This factor will influence the level of G6PD activity found in the 
sample. 
(III) As mentioned in section 1.2, the equilibrium coefficient of a G6PD reaction is 
closed to 1; the oxidation of G6P only takes place in the cell due to the presence 
of the G6PD enzyme and two other subsequent enzymes in the PPP that helps to 
consume the product of the reaction. This means G6PD oxidation will be 
incomplete unless the product is removed by the second enzyme, 6PGL. 
However, it is unclear how much lactonase is present in the crude lysate or if it 
varies from individual to individual. If 6PGL is limiting or absent, then NADPH 
will accumulate and block the pathway. This will not only affect the detection but 
can be lethal. 
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1.7 The non-medical significance of G6PD
There are various biochemical protocols that require NADPH.69, 70, 71 This is an unstable and 
costly reagent so that it is typically produced via system that involves the enzymatic 
conversion from NADP+. Developing an efficient and robust system for generating NADPH 
would of be commercial value.
Given its importance, relatively little is known of the detailed mechanics of G6PD function. 
A catalytic mechanism, similar to that of a number of other dehydrogenases has been 
proposed34 and an understanding of its regulation by NADPH has been put forward.1, 13, 25, 26 
but the details of how a change in oligomeric structure is achieved and how this affects 
activity is not clear.
1.8 Overview of Thesis
To address the problems mentioned in section 1.6.2, this project set out with the following 
aims: 
(I) To develop a sensitive assay for G6PD. Ideally, this assay should be capable of 
being converted for use in the field.(II) To engineer a stable and active form of E. coli G6PD via directed evolution that 
would serve as a positive control for the assay in aim I. In addition, this enzyme 
could be applied to NADPH regeneration. 
(III) To examine and characterize the properties of wild-type and mutant forms of E. 
coli G6PD to gain a better understanding of its regulation and the factors that 
affect its stability.
In the following chapter, the routine experimental methods used throughout the research are 
described. In chapter 3, the development of a new and sensitive assay for E. coli G6PD is 
outlined. Later, in Chapter 4, the development of thermally stable G6PD variants using 
directed evolution studies is described. This chapter also described the improvised high-
throughput screening method to determine G6PD enzyme activity in the crude cell lysate, 
which is adapted from the assay developed in the previous chapter. Subsequently, the 
research to gain a better understanding of the functional properties and the oligomerization 
pattern of the thermostable variants are described in Chapter 5 and 6, respectively. Finally, 
Chapter 7 draws the conclusions and future recommendation for this project.
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CHAPTER 2
General Experimental
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2.1       Preamble
This chapter gives details of routine experimental procedures that were used throughout this 
project. It comprises the details of commonly used techniques of molecular biology. 
Information regarding specific and developed protocols is given in the relevant chapters.
Distilled water was obtained from Milli-Q Reagent water system. All chemicals and reagents 
used were of analytical grade. Growth media, glassware, microcentrifuge tubes, micropipette 
tips, buffers, and solutions for molecular biology and culture work were sterilized by 
autoclaving using ASB270BT autoclave machine (Astell Scientific). 
2.2 Bacterial strains and their growth
Two strains of E. coli, DH5α and BL21 (DE3), were used in this study. These are common 
laboratory strains and will only be described briefly, along with the protocols used to grow 
them. Most of the protocols were obtained from the laboratory manual for cloning by 
Sambrook and Russell.1
2.2.1 Strains
DH5α was used for all applications except in protein expression, in which case BL21(DE3) 
was used. DH5α is an E. coli K12 strain that has a number of features that make it suitable 
for the work described in later chapters:
1) It is known for its high transformation efficiency, is relatively simple to 
prepare and is easily stored.
2) It is recA-: that is recombination deficient to avoid recombination of 
transformed homologous sequences into the bacterial genome.
3) endA – this eliminates expression of a non-specific endonucleases, thus 
avoiding difficulties that would otherwise be associated with plasmid 
preparation.
4) hsdR17 – This results in the removal of a restriction enzyme that would 
otherwise degrade foreign DNA transformed into the cell. 
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BL21 (DE3) was used as the host for high-level protein expression.  For this, the gene was 
cloned into T7 expression vectors (pET vectors). The BL21 strain and the pET vectors have 
been described in great detail elsewhere2 and only a brief description of the expression 
system will be given here. The gene for T7 RNA polymerase has been incorporated into the 
BL21 chromosome downstream of the lacUV5 promoter. IPTG was used to induce 
expression of T7 RNA polymerase that then transcribes the target genes located downstream 
of the T7 promoter in the plasmid.2 The lon and ompT genes that code for proteases have 
been inactivated to reduce proteolytic degradation of the target protein during expression.3
2.2.2 Growth media and culture growth
The growth media used for most culture work in this study was Lysogeny Broth (LB − 10 
g/L tryptone, 5 g/L yeast extract, 10 g/L NaC1, pH 7.0) unless stated otherwise. Each media 
was supplemented with antibiotics (100 μg/mL ampicillin unless stated otherwise) in 
accordance with the antibiotic resistance that the plasmids used confer.
For culture work, single colonies isolated from LB plates were used to inoculate all broth 
cultures. For broth cultures larger than 20 mL, an overnight starter cultures consisting of 1% 
of the final culture volume were used for subculturing.  Cultures smaller than 5 mL were 
grown in 10 mL or 15 mL tubes, while larger cultures were grown in baffled flasks. Cultures 
were grown at 37 °C with agitation unless otherwise stated.
2.2.3 Preparation of cells for electroporation
The protocol for preparation of electrocompetent cells was adopted from Sambrook and 
Russell.1 A single colony was used to inoculate 8 mL of Yen B broth (7.5 g/L yeast extract 
and 8 g/L nutrient broth) and grown overnight as a starter culture. This culture was then 
added to 800 mL of Yen B and was grown at 37 °C until the OD600 was in the range of 0.6 - 
0.8 (normally within 3- 4 hours). The culture was then cooled at 4 °C prior to centrifugation. 
From this point onwards, the culture was kept at 4 °C as much as possible. All buffers and 
solutions used were also pre-cooled at 4 °C. The culture was centrifuged at 5, 000 rpm in a 
VWR R9A rotor, at 4 °C for 10 minutes. The supernatant was discarded and the pellet was 
re-suspended by gently swirling with 200 mL of sterile distilled Milli-Q water for washing. 
This stage was performed twice. The cells was then centrifuged and washed with 200 mL of 
10% glycerol. The cells was then centrifuged as before and the cell pellet was re-suspended 
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in 0.5-1.0 mL of 10% glycerol. The cells was then aliquoted into 50 μL aliquots, snap frozen 
with dry ice, and stored at -80 °C. All competent cells were plated on Lysogeny Broth agar 
plate supplemented with ampicillin (LBA) and Lysogeny Broth agar plate supplemented 
with kanamycin (LBK) to check for contamination and was transformed with 1 ng of 
pJWL1030 plasmid to check for competency.
2.3 Plasmid DNA and manipulations
This section describes the plasmids used in this project along with the methods used to 
manipulate them: isolation, digestion, and ligation. Methods involving PCR can be found in 
Section 2.4. 
2.3.1 Description of plasmids
(i) pCY76
The pCY76 (par+, bla+, lacZpro, T7!10tir+) is a high-copy number vector that allowed 
constitutive expression of non-toxic genes in E. coli. Expression was under the 
control of the lac promoter. The partition element (par) aids in maintenance of 
plasmid copy number (stability) while the bla gene encodes beta-lactamase for 
ampicillin resistance. Its construction has been previously described.4 Briefly, the 
plasmid was constructed from two plasmids: the translational initiation region, RBS 
and Multiple Cloning Site (MCS) components from pND7065, and the backbone 
from pMTL22P.6
(ii) pETMCSIII
This vector was a gift from Professor Nick Dixon of the University of Wollongong. It 
is a modified vector derived from T7 pET vectors initially created by Studier.7 For 
details of the construction of this vector, see the work done by Neylon and co-
workers.8 The modification was simply the introduction of an NdeI restriction site 
into the MCS, downstream of the RBS. This plasmid codes for an N-terminal His-
tags upstream of the NdeI site. Unlike some pET vectors from Novagen, this vector 
lacks the LacI repressor gene, thus allowing leaky expression. pETMCSIII confers 
ampicillin resistance to the host. 
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(iii) pHUE
This vector was constructed by modifying the T7–based expression vector (pET15b) 
created by Rohan et al.9 for expression of His-tagged Ubiquitin fusion protein. The 
plasmid map contains the inducible T7 RNA polymerase promoter, His-tag at the C-
terminal of ubiquitin open reading frame and an extended polylinker. Target gene 
was inserted between SacII and EcoRI restriction sites to form a fusion protein with 
the Ubiquitin − a small protein helps to increase the solubility of its fusion partner. 
The presence of His-tag attached at the 5’ ends of the Ubiquitin makes it suitable for 
Ni2+ column purification. Prior to purification, the Ubiquitin was cut off from a 
protease cleavage site between the target protein and the Ubiquitin using specific 
protease.
2.3.2 Plasmid isolation
Plasmids were purified using the QIAprep Spin Miniprep kit (QIAGEN) according to the 
standard protocol given in the manual. The buffers used in this procedure were provided by 
the manufacturer. The procedure, in brief, was as follows: 1-10 mL overnight culture was 
pelleted and the supernatant was discarded before re-suspended in Buffer P1. Buffer P2 was 
added to lyse the cell, followed by Buffer P3 to neutralize the solution. The mixture was 
mixed well and pelleted by centrifugation at maximum speed for 10 min. The supernatant 
was loaded into a spin column to bind DNA. The column was then washed with PW2 buffer 
containing ethanol. Finally, the DNA was eluted with elution buffer or Milli-Q water. 
2.3.3 DNA fragment purification
Two types of DNA purification methods were used: DNA gel extraction and DNA PCR 
purification. The method used depended on the DNA and overall workflow. Both methods 
utilized Wizard SV gel and PCR Clean-up System from Promega and were performed 
according to the manufacturer’s instructions. In brief, for PCR purification clean up, 
membrane binding solution was added to the PCR product at a ratio of 1:1 (v/v), while for 
agarose gel DNA extraction, a 1:10 (w/v) ratio was added to the agarose gel and incubated at 
65 °C for 10 min to melt. The dissolved solution was then applied to DNA binding column 
and washed two times with washing buffer containing ethanol. The DNA was then eluted 
with Milli-Q water.
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2.3.4 DNA visualization
All DNA samples were analyzed with 0.8-1.0% agarose gel electrophoresis, depending on 
the size of DNA fragments to be separated. 0.8 to 1.0 g of agarose was added in 100 mL of 
SB buffer and boiled to enable the agarose to dissolve. The mixture was then cooled slightly 
and 5 uL of 1x Red SafeTM (iNtRON, Korea) DNA stain was added. The mixture was then 
poured to solidify onto 125 mm x 80 mm flat glass plate so that the gel formed by surface 
tension.  Prior to sample loading, DNA sample was mixed with bromophenol blue loading 
dye (10 mM Tris pH 8.0, 10% (w/v) of bromophenol blue and 40% (v/v) glycerol) at a 
volume ratio of 5:1 (DNA: loading dye). The settings for electrophoresis were 120 Volt for 
30-45 minutes in 1xSB buffer.10 After electrophoresis, the gels were visualized under weak 
UV (365 nm), strong UV (254 nm) or blue LED array box for fluorescence. Images of gel 
were taken using UVI Pro electronic system.
2.3.5 DNA quantification
DNA concentration was determined using NanoDrop ND-1000 spectrophotometer by 
observing the absorption at 260 nm and the absorption at 280 nm was also measured to gain 
an indication of sample purity. A ratio of OD260 to OD280 greater than 1.8 was regarded as 
‘pure’ and was required for further manipulation. DNA concentration was estimated using 
Nanodrop software setting “dsDNA-50”. 
 2.3.6 Restriction digest
New England Biolabs (NEB) provided the restriction endonucleases used in this project. 
Enzymes were used according to the manufacturer’s instructions. 10-20 Units (U) of the 
enzyme was added to 2-3 μg of DNA in 10x Cut Smart buffer. The mixture was incubated at 
37 °C for 3 hours before heat inactivated at 65 °C for 20 minutes. Digested vector plasmid 
was then treated with alkaline phosphatase as described below (section 2.3.7). Digested PCR 
product was purified without phosphatase treatment. For PCR product for mutagenesis, DpnI 
was added together with the restriction enzyme to digest methylated template plasmid DNA 
and reduce the occurrence of parental genes in subsequent libraries. After digestion, the 
sample was run on agarose gel for extraction. 
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2.3.7 Alkaline phosphatase treatment
Digested plasmid DNA was dephosphorylated with calf-intestinal alkaline phosphatase 
(CIP) from NEB to prevent self-ligation of the vector. 10 U of the CIP was added into 
digested plasmid and incubated at 37 °C for 2 hours. CIP-treated DNA was purified as 
described in section 2.3.3.
2.3.8 DNA ligation
T4 Ligase used in this study was purchased from Thermo Scientific and Roche. Ligation was 
performed with a molar ratio of insert to vector at 3 to 1. The molar ratio was altered and 
optimized if the subsequent colony count after transformation was not satisfactory. 1.5-7.5 U 
of T4 ligase was added to the vector-insert mixture and was incubated overnight at 16 °C. 
The final volume used for ligation was 20 μL. The ligation product was purified using PCR 
purification kit as described in section 2.3.3. This step was done to lower the ionic strength 
of the ligation to enhance the transformation efficiency.
2.3.9 Bacterial transformation
Electroporation was used to transform cells. Briefly, 1-5 μL of DNA solution was added 
gently to 50 μL of thawed electrocompetent cells and were mixed thoroughly by gentle 
pipetting or flicking. The mixtures were then kept on ice for 10 minutes and transferred to 
pre-chilled 0.2 mm electroporation cuvettes. Electroporation was carried out with a Bio-Rad 
MicroPulserTM using a potential difference of 2.5 kV over approximately 5 ms (EC2 setting). 
The electroporated cells were immediately resuspended in 1 mL of YENB broth and were 
incubated at 37 °C for one hour with agitation for recovery. The transformed cells (50 μL), 
with or without dilution were then plated on LB plates supplemented with antibiotics and 
grown overnight at 37 °C. Electroporation cuvettes were rinsed with distilled water, soaked 
in 70% ethanol and dried for reuse.
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2.4 Polymerase chain reaction (PCR)
This section covers procedures for general DNA fragment amplification as well as DNA 
sequencing. It assumes a basic knowledge of PCR that has been covered in reviews and basic 
texts. PCR protocols for the introduction of mutations will be described in the next section 
(Section 2.5) that deals with directed evolution.
2.4.1 Primer design
All the primers used in this work are listed in Appendix A. All the primers used were 
ordered from GeneWorks or Integrated DNA Technologies (IDT). Web-based computational 
software, Oligo Calc Properties Calculator was used to estimate the melting temperature 
(Tm) and GC content of the primer and template DNA.11 
(http://www.basic.northwestern.edu/biotools/OligoCalc.html)
2.4.2 Basic PCR
Thermocyclers used for this project were, GeneAmp CR system 9700 (Applied Biosystems), 
iCycler (Bio-Rad), C1000 Thermocycler (Bio-Rad), MJ Mini Personal Thermal Cycler (Bio-
Rad) and Veriti Thermal Cycler (Applied Biosystems). 
When accurate amplification was required, i.e. constructing new plasmid and long-range 
PCR, high fidelity DNA polymerases such as pfu (Thermo Scientific) and Phusion (NEB) 
were used as per manufacturer’s protocol. For routine amplification, Taq polymerase 
(Bioline; Roche) was used. 
The reaction mixture contained 50-150 ng of template DNA and 1 μM forward and reversed 
primer each. Magnesium ions was added as follows: 1.5 mM MgC12 of Taq polymerase, 
Biotaq, and Phusion or 2 mM of MgSO4 for Pfu polymerase. Nucleotides (0.2 mM of each 
dNTP) as well as 1.25-2.5 U of DNA polymerase, were added to each reaction. The cycling 
conditions used in this work are shown in Table 2.1.
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Table 2.1 The basic PCR protocol for amplification
Initial 
denaturation 94/98 °C (for Phusion) 2-5 min
30-35 cycles
Annealing Avg Tm for 2 primers- 5 °C 10-30 s
Extension 72 °C 1 min/kb DNA for Taq, 
2 min/kb for pfu, 
15-45 s/kb for Phusion, 
15-30 s/kb for Biotaq
Denaturation 94/98 °C (for Phusion) 10-30 s
Final annealing Avg Tm for 2 primers-5 °C 2 min
Final extension 72 °C 5 min
2.4.3 Colony PCR
Colony PCR is a rapid and easy technique to verify the presence of intended gene before 
proceeding to other applications, like DNA sequencing. This is carried out after transforming 
a new plasmid construct or a new mutagenic library. The technique has been described in 
detail elsewhere and only the experimental details will be given here.  In brief, a master mix 
for the reaction containing 1 μM of each forward and reverse primer, 1.5 mM MgCl2, 0.2 
mM of each dNTP and 1.25 U of Taq polymerase (Bioline/Roche) was prepared. Single 
colonies were picked and resuspended in 5 μL Milli-Q water. 1 μL of the resuspended cell 
mixtures were then transferred into the aliquoted PCR mix prepared.  The reaction was 
performed in 20 μL reactions. PCR was carried out using a 5 minutes denaturation step at 95 
°C to ensure complete cell lysis, followed by 35 cycles of amplification, which consist of 30 
seconds denaturation at 94 °C, annealing at 50 °C for 30 seconds, and extension at 72 °C for 
1 minute.
2.4.4 DNA sequencing
DNA sequencing was done at the ACRF Biomolecular Resource Facility (BRF) in John 
Curtin School of Medical Research (JCMSR) at the Australian National University. Samples 
were prepared according to the guidelines given on their website.12 Each PCR reaction 
consisted of 150-300 ng plasmid DNA, 3.2 pmol primers, 1 μL of BigDye Terminator and 
1x Sequencing Buffer. Distilled water was added to the mixture to a final volume of 20 μL. 
The cycling conditions are outlined in Table 2.2.
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Table 2.2 PCR condition for DNA sequencing
Stage Temperature (°C) Time
Initial denaturation 94 5 min
(30-50 cycles)
Denaturation 96 10 s
Annealing 50 5 min
Extension 60 4 min
DNA was cleaned up with ethanol precipitation prior to sequencing. A cleanup mixture 
containing 62.5 μL of 100% ethanol, 3 μL of 3 M sodium acetate pH 4.6 and 14.5 μL 
distilled water was added to the PCR product and mixed thoroughly. Cleanup samples were 
then left to stand at room temperature for 15 minutes. The samples were then centrifuged at 
maximum speed for 30 minutes and the supernatants were discarded by inverting the plate. 
The inverted plate was then centrifuged at 300 rpm for 1 minute. The pellet was washed with 
200 μL of 70% ethanol and centrifuged for 10 minutes. The supernatant was then removed, 
and the sample was air dried in the dark before being sent to BRF for sequencing. DNA 
sequencing chromatograms were viewed using Sequencher 4.10.1 (Gene Codes Corp).
2.5 Directed evolution and protein engineering
Most of the experimental procedures used for directed evolution experiments are discussed 
in this section. Details specific to a particular set of experiment are given in the relevant 
chapters.
There are two main steps in directed evolution − producing a library of mutated genes and 
screening the expressed proteins for a desired property. Library generation involves the 
introduction of genetic diversity using PCR technique such as ePCR and StEP-ePCR that are 
described below. The resulting PCR products from the reactions were digested with 
appropriate restriction enzymes and cloned into the desired vector as described in Section 2.3 
and 2.4. The library was then transformed and screened using methods that vary from one 
application to another – these will be described in the appropriate chapters.
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2.5.1 Error-prone PCR (ePCR)
The most common method used to introduce random mutations into a gene was by error-
prone PCR (ePCR). This can be achieved by numerous method that is described 
elsewhere13,14,15; the important point is that all these methods involve lowering the fidelity of 
Taq polymerase. For the current project, fidelity was lowered by manipulating 
concentrations of MgCl2 and MnCl2. The protocol was adapted from a protocol by Cadwell 
et al.16 and Arnold et al.17 ePCR uses higher MgCl2 (5 mM) than standard PCR (1.5 mM) to 
stabilize non-complementary pairs due to mutation incorporation, while MnC12 was added to 
reduce the specificity and therefore fidelity of the DNA polymerase. An increased amount of 
Taq polymerase was used to encourage nucleotide extension beyond the positions of base 
mismatch.16 In this work, the typical strategy was to prepare multiple ePCR reactions with 
various MnCl2 concentrations and to pool the ePCR products to obtain a mutagenic library 
with wide range of mutation rates. A typical ePCR set-up is as in Table 2.3. 
Table 2.3 Reaction set-up for ePCR
Component Volume (μL)
Plasmid DNA (50-150 ng/μL) 1
Forward primer (10 μM) 5
Reverse primer (10 μM) 5
PCR buffer (without MgCl2) 5
MgCl2  (50 mM) 5
MnC12 (50 mM) 1-2
dNTPs (40 μM combined) 1
Taq polymerase (5 U μL-1) 0.5
Water 25.5-25.5
Total 50
The cycling condition is identical to standard amplification described in section 2.4.2. For 
subsequent rounds when shuffling was applied, ePCR was combined with a staggered 
extension process (StEP) as described in section 2.5.3.
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2.5.2 Staggered extension process (StEP)
StEP is an in vitro recombination process and was first described by Zhao et al.18, 19 This 
protocol uses shorter extension time to allow random template swapping during cycles of 
denaturation and annealing.20 In this work, StEP was used to shuffle mutations generated 
from ePCR. The StEP PCR reaction set-up consisted 30 ng of template, 1 μM of each 
forward and reverse primer, 0.2 mM of each dNTP and 1.5 mM MgCl2. The cycling 
conditions is as in Table 2.4.
Table 2.4 PCR cycling condition for staggered extension process (StEP)
Initial 
denaturation
94/98 °C (for Phusion) 5 min
120 cycles
Denaturation 94/ 98 °C (for Phusion) 10 s
Annealing 55 °C 10 s
Extension 72 °C 2 s
Final annealing 55 °C 2 min
Final extension 72 °C 5 min
2.5.3 StEP-ePCR
StEP-ePCR is a one-step procedure that incorporates both shuffling and error-prone PCR in 
a single reaction. The protocol was used after template switching and it was observed at very 
low frequency in ePCR.17 In this work, StEP-ePCR was typically introduced from the second 
round of evolution onwards, to introduce new mutations in addition to shuffling the 
mutations obtained from the first round. The cycling conditions for the reaction is described 
in Table 2.5.
Table 2.5 Cycling conditions for StEP-ePCR
Initial denaturation 94/98 °C (for Phusion) 5 min
120 cycles
Denaturation 94/ 98 °C (for Phusion) 10 s
Annealing 55 °C 10 s
Extension 72 °C 2 s
Final annealing 55 °C 2 min
Final extension 72 °C 5 min
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2.5.4 Analysis of mutant library
Whenever a mutagenic library was generated, its quality was determined. Firstly, colony 
PCR (refer Section 2.4.3) was performed to check the presence of plasmid harboring the 
mutated gene of interest. After the correct library was confirmed, parameters such as library 
size and average mutation frequency were determined. The library size was quantified by 
estimating the number of colony-forming units (cfu) on agar plates supplemented with 
antibiotics. Usually, several dilutions of the transformants were plated on agar plates. The 
library size per transformation was then estimated from the mean of cfu of the agar plates 
with different cell dilutions.
The average mutation frequency was estimated by determining the number of mutations in 
10-15 randomly selected colonies. The mutation frequency was expressed as the mean and 
standard deviation of the number mutations found. Colony PCR was also performed as 
described in section 2.4.3 to ascertain the presence of plasmid harboring the mutant gene.
2.6 Protein manipulation
In this section, only routine protocols that were used on a day-to-day basis are covered. This 
includes protein visualization and quantification. Techniques that were not routine, such as 
native gels (Chapter 6), are not included as are protocols that were modified or developed by 
myself. These latter techniques are described in Chapter 3 and include: protein expression, 
purification, dialysis, and subsequent storage.
2.6.1 Protein visualization
SDS-PAGE  (Laemmli) was used to visualize the protein.21 The method separated the 
protein according to their monomeric molecular weight. In this study, 15% (w/v) of 
resolving gel and 4% (w/v) of stacking gel were used. Details of the ingredients used are 
listed in Table 2.6.
37
Table 2.6 Ingredients for SDS-PAGE
Two Minigels of short plate Resolving Gel Stacking Gel
Percentage (%) 15 4
Volume (uL) 8000 3333
40% Acryl-Bis 3000 375
1.5 M Tris pH 8.8 2000 -
0.5 M Tris pH 6.8 - 833
10% SDS 80 33.3
Milli-Q water 2850 2070
10% Ammonium persulfate
Thermo Scientific (APS)
60 20
Tetramethylethylenediamine 
(TEMED)
10 3
The protein samples were prepared at ratio of 1:2 with premixed cracking buffer (0.1% 
bromophenol blue, 80% glycerol, 8% (v/v) of 2 M Tris buffer pH 6.8, 10 % SDS, 0.03 g/mL 
of dithiothereitol) containing 10% 2-mercaptoethanol. The mixtures were then denatured at 
95 °C for 3 min using heat block prior to loading into the wells of SDS-PAGE gel. 5-10 μL 
of sample was loaded into each well. A low molecular weight marker (Bio-Rad) was used as 
protein marker. The gels were run in 1x Tris-glycine buffer at pH 8.3 at 200 V per gel for 
roughly 30-45 minutes.
2.6.2 Protein quantification
Protein concentration was determined by measuring the absorbance of 1-2 μL of sample at 
280 nm using a Nanodrop spectrophotometer.22 Each protein sample was measured at least 
twice. The protein concentration was calculated from the A280 values obtained based on the 
Beer-Lambert equation that is given in Equation 2.1. The protein extinction coefficient was 
estimated by ProtParam tool (http://web.expasy.org/protparam/). The theoretical extinction 
coefficient for native E. coli G6PD used in this study was 86860 M-1 cm-1.
A=e.c.l          ----------------------------------------------------------------- (Equation 2.1)
A: Absorbance
e: Molar absorption coefficient (M-1 cm-1)
l: cell pathlenght (cm)
c: Concentration (M)
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2.6.3 Protein molecular weight determination
Size exclusion chromatography was the method applied for molecular weight determination 
in this work. The method will be explained in detail in Chapter 6.
2.7 Software programs
DNA sequences were analyzed using Sequencher 4.10.1.1. Multiple DNA and protein 
sequence alignments were done with Clustal-Omega.23 In this study, the E. coli G6PD 
protein was aligned with several sequences from human (PDB: 1QKI)24, L. mesenteroides 
(PDB: 1E7Y)25 and Tryponosoma cruzi (PDB: 4ei9b)26
(http://www.ebi.ac.uk/Tools/msa/clustalo/).
Phyre2 web server (http://www.sbg.bio.ic.ac.uk/phyre2)27 was used to generate predicted 
structure and phylogenetic relationship between homologous sequences by using the wild-
type E. coli G6PD sequence (Appendix B). PyMOL was used to visualize the protein 
structure and generated the protein structural figures used in this work 
(https://www.pymol.org/).
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CHAPTER 3
Developing a sensitive assay for G6PD using a 
coupling reaction with downstream enzymes
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3.1 Preamble
This chapter describes the development of a sensitive 
assay for E. coli G6PD activity. The term sensitive is 
meant to imply the ability to detect enzyme activity at 
low substrate concentrations. The motivation and 
rationale for this work have been described in the 
introduction of this thesis. Two approaches were taken to 
improving the sensitivity of the assay. Firstly, minor 
modifications were made to the colorimetric enzyme 
assay developed by Tantular et al.1 This approach 
increased the sensitivity by recycling NADPH through 
the production of a dye with a much higher extinction 
coefficient than NADPH. The second approach involved 
the addition of two downstream enzymes from the 
Pentose Phosphate pathway (PPP): 6-phosphogluconolactonase (6PGL), and 6-
phosphogluconate dehydrogenase (6PGD). These enzymes rapidly remove the product of the 
G6PD reaction thus preventing any back-reaction from occurring. Besides, the two 
downstream enzymes increase the amount of colored dye by a factor of two. Once 
optimized, the new assay was used to measure the kinetic parameters for the reaction 
catalyzed by G6PD.
3.2 Introduction
3.2.1 Background: Assay detection for G6PD
The usual method used to assay G6PD activity involves oxidation of the substrate G6P to 6-
phosphogluconolactone (PGL) by G6PD with concomitant reduction of NADP+ to NADPH, 
that is measured at 340 nm (Figure 3.1). As noted in Chapter 1, the equilibrium favors the 
formation of G6P rather than the PGL. This back-reaction can be prevented by recycling the 
NADPH. However, the build-up PGL will tend to slow further oxidation of G6P (as we 
demonstrate later in this chapter). There are some methods that can be used to recycle the 
NADH or NADPH utilized in Redox reactions. For example, tetrazolium salts can be 
coupled with an electron transfer reagent to monitor the G6PD reaction. The water-soluble 
tetrazolium salts series namely WST-1, WST-3, and WST-8 provided both stability and 
sensitivity to the measurement of G6PD activity.2 The reaction involves the conversions of 
Figure 3.1 A common single G6PD
reaction measured at 340 nm using
spectrophotometer
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NADPH to NADP+ and the reduction of the tetrazolium salt WST-8 to give a water-soluble 
orange coloured formazan. As shown in Figure 3.2, this reaction requires an electron carrier, 
such as phenazine methosulfate (PMS) an electron mediator. This reaction gives rise to the 
formation of a coloured product that is easily detected with a microplate reader so that the 
extent of the reaction can be quantified. The use of WST-8 is particularly useful in field tests 
for G6PD activity. In this study, two dyes were tested, and the suitability and sensitivity of 
the dyes were observed for the G6PD reaction.
G6P
6-
6PGL
NADPH (red.)
NADP
+
(oxi.)
Orange
formazan
PMSG6PD
340 nm
460 nm 600 nm
(red.)
(oxi.)
Dye (s)
WST-8 DCPIP
G6P
6PGL
NADPH (red.)
NADP+ (oxi.)
G6PD
WST-8 DCPIPor
Dye
Orange
formazan Colourless
(oxi.)
(red.)
460 nm 600 nm
PMS
Normal laboratory assay at UV range Applicable for both laboratory and field assay
340 nm
Figure 3.2 Mechanism of the reaction for detection of G6PD using WST- 8 and DCPIP. 
Abbreviations: G6P,glucose-6-phosphate; G6PD, glucose-6-phosphate dehydrogenase; 6PGL, 6-
phosphogluconolactonase; DCPIP, 2, 6-dichloroindophenol
The second approach to improving the G6PD assay was to add the two downstream enzymes 
from the PPP. This was achieved by adding an excess of purified enzymes to the reaction 
mix. The resulting reaction is shown below in Figure 3.3. The enzymes were expensive if 
obtained from a commercial supplier, so it was decided to express them from two organisms, 
and test to see if they expressed well and were stable. 
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Figure 3.3 Principle of coupling assay for G6PD. (A) The illustrated diagram above the dotted red 
line indicated the commercial G6PD couple assay with a WST- 8 dye. (B) The proposed coupling 
assay for G6PD with the two downstream enzymes in the PPP. The blue and the yellow arrows 
indicated the downstream enzymes. 
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3.3 Materials and methods
3.3.1 Materials
The WST-8, 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H 
tetrazolium monosodium salt was synthesized by Assoc. Prof Ross from the University of 
Queensland. It was prepared according to the procedure described by Ishiyama et al.2 The 
other dye, DCPIP (2,6-dichloroindophenol) and coupling agent PMS, were purchased from 
Amresco. The chemicals used are analytical standard. Assay mixtures used in this studies 
included, 0.02 mM PMS, 0.5 mM WST-8, 0.01 mM NADP+, 0.05 mM G6P, 10 mM MgCl2 
and 0.1 M Tris-HCI pH 7.65.
3.3.2 Preparation of detection reagents
Tetrazolium salt WST-8 and DCPIP were dissolved in Milli-Q water at a concentration of 5 
mM. Because DCPIP was not soluble, the Milli-Q water was pre-heated at 50 °C before 
dissolving. Electron mediator PMS was dissolved in Milli-Q water at 20 mM. The detection 
reagents were added individually into 190 μL reaction mixtures.
3.3.3 Methods
3.3.3.1 Expression of WT G6PD, 6PGL and 6PGD gene for purification
The genes used in this study were from Ollis laboratory stock cultures. They were obtained 
from two sets of plasmids that harbored the desired genes for this study − they originated 
from E. coli or Zymomonas mobilis. The availability of Z. mobilis in the laboratory stock 
culture led to this plasmid being selected as possible alternatives to those from E. coli and 
commercials. PCR was used to obtain the genes with NdeI and EcoRI restriction sites at the 
start and end of the gene, respectively. The genes were then cloned into the pETMCSIII 
vector so that the proteins could be expressed with N-terminal poly-Histidine tags using E. 
coli BL21 (DE3). The pETMCSIII vector is a modified form of the pET vector that was 
originally constructed and described by Studier.3 Chapter 2 has a more detailed description 
of the strains and the vectors used in this work. For 6PGL enzyme from E. coli, the solubility 
and the expression were low. Hence, the gene was cloned into pHUE vector to facilitate the 
expression and solubility. The pHUE vector enables co-expression of the gene with ubiquitin 
poly-Histidine tags, which is cleavable after purification. Details of this vector were 
described in Chapter 2.
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3.3.3.2 Protein expression and purification
All three proteins used in this work were expressed with poly-Histidine tags to facilitate 
purification. They were purified using essentially the same method described below.
An overnight culture was grown in 1 L of two times yeast extract broth at 37 °C (2XYT: 10 
g/L tryptone, 10 g/L yeast extract, 10 g/L NaCl, 100 μg/mL ampicillin). The overnight 
culture was grown with shaking in 10% volume of the expression culture volume. This was 
used to inoculate the 2XYT media for culture growth. The culture was expressed at 37 °C 
with shaking at 180 rpm. The culture was then induced with 0.5 mM IPTG at OD600 of 0.6-
0.8 and then expressed for another 3 hours at 37 °C. Cells were harvested at 4 °C by 
centrifugation at 5000 rcf for 20 minutes. 
The pellet was re-suspended in 25-30 mL of Buffer A that consisted of 50mM Phosphate 
buffer at pH 6.5 containing 300 mM NaC1. The cells in the re-suspended pellet were either 
be lysed directly or stored at -80 °C for further use. Cells were lysed with a sonicator−twice 
for 8 minutes on ice. The lysed sample was centrifuged at 16,000 rcf to remove insoluble 
components. The soluble supernatant was loaded in Buffer A onto a 5 mL His-Trap Nickel 
column and was eluted using a gradient that consisted of a mix of Buffer A and Buffer B. 
Buffer B, the elution buffer was similar to Buffer A with the addition of 500 mM imidazole. 
An Akta FPLC instrument was used for the purification and was equipped with Unicorn 
Software from Amersham Pharmacia Biotech. The protein eluted using gradient profile as 
illustrated in Figure 3.4. A Flow rate of 3.0 mL/min was used and 5 mL fractions were 
collected each. A gradient of 10% to 100% Buffer B was used to elute the targeted protein. 
The nonspecific protein was eluted at range of 15-25% gradient, while the target protein was 
eluted with around 50-100% gradient (for 6PGL) and 100% gradient for both G6PD and 
6PGD. Protein purity was verified using 15% SDS-PAGE gel and the right size of proteins 
was pooled for dialysis.  Assays were only carried out with proteins that were at least 90% 
pure as judged by an inspection of the SDS-PAGE gel.
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Figure 3.4 The general elution profile for His-Trap purifications. The dotted line shows the region of 
5mL fractions collected. The green line indicates the gradient of buffers (The black dotted line shows 
the peak for the target protein, while the orange doted line shows the peak for impurities).
3.3.3.3 Protein dialysis and storage
The pooled purified proteins were in Buffer B with 75-100% imidazole after the purification. 
The pooled protein was concentrated until 0.25 mL using an Amicon Ultra Centrifugal filter 
(30 kDa molecular weight cutoff; Millipore) at 4000 g at 4 °C. After that, the concentrated 
protein was serially diluted with a buffer containing only 50 mM phosphate at pH 6.5 to 
remove the salt and the imidazole. Both salt and imidazole were removed by serial dilution, 
where 10 mL of buffer was added to 0.25 mL concentrated protein and centrifuged for one 
hour. The procedures were repeated six to seven times to remove the salt completely. The 
desalted proteins were kept at 4 °C for immediate use or 50% glycerol was added for long-
term storage at -20 °C. When investigating enzyme kinetics, freshly purified protein was 
used within a week. The protein preserved in the glycerol was used for other experiments to 
characterize the protein. For the assays, the protein was diluted and the percentage of the 
glycerol in the assay was kept constant at less than 1%.
3.3.3.4   Colorimetric enzyme assay using WST-8 and DCPIP
3.3.3.4.1 Optimization of assay
The method developed by Tantular and Kawamoto1 was modified to suit the E. coli G6PDWT 
enzyme and the equipment available in the laboratory. Two dyes, WST-8 and DCPIP, were 
tested to determine the suitability and productivity with E. coli G6PD. For the optimization, 
WST-8/PMS was used and the optimized condition was applied to DCPIP/PMS assay. A 
total assay volume of 200 μL was used for each reaction. The effects of varying the 
concentrations of G6P, NADP+, WST-8 and PMS to the absorbance of the formazan product 
produced at 460 nm were observed.
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Initially, high concentrations of reagents were used at 0.1 M Tris-HCI pH 7.65, 10 mM 
MgCl2, and 0.25 mM NADP+, 0.25 mM G6P, 0.5 mM PMS and 1 mM WST-8. Then, the 
concentration of substrates, dyes, and the electron mediator were adjusted to get a 
reproducible linear slope for measurements of G6PD activity. Concentrations of parameters 
ranging from 0.01 to 1 mM were tested. For the assay, 10 μL of each reagents: 0.1 M Tris-
HCI pH 7.65, 10 mM MgC12, 0.25 mM NADP+, 0.5 mM PMS, 1 mM WST-8, and 0.15 μM 
of G6PD enzyme was pipetted into individual wells of a flat- bottom 96-well plates, and 
Milli-Q water was added to make a total of 150 μL of reagent solution. The G6PD reaction 
was initiated by the addition of 50 μL of G6P, and the absorbance at 460 nm was measured 
for 90 sec at 25 °C with a plate reader. A similar approach was applied for assay with 
DCPIP/PMS that was carried out over 90 sec  with the temperature adjusted to 25 °C and the 
wavelength set to 600 nm.
3.3.3.4.2 Coupled G6PD reaction - equal amount of downstream enzymes
Initially, tests were done with concentrations of downstream enzymes equal to that of G6PD 
(1:1). A 10 μL of each enzyme, substrate, NADP+, dyes: WST-8 or DCPIP, electron 
mediator: PMS and 20 μL of Tris-HCI buffer with Mg2+ at pH 7.65 was added individually 
into respective well of a 96-well plates (flat bottom), making up a final concentration of 0.3 
μM of each enzyme, 50 μM G6P, 10 μM NADP+, 20 μM PMS, 500 μM WST-8/DCPIP and 
0.1 M Tris-HCl with 10 mM Mg2+.  Milli-Q water was added to top up the 200 μL of 
reaction mixtures. Each enzyme was added individually (see illustration in Figure 3.5). 10 
μL of G6P was added to start the reaction. The assay was performed by measuring the 
formazan produced at 460 nm for WST-8 and 600 nm for DCPIP at 25 °C for 3 minutes.
Figure 3.5 Diagrams of different enzymes combinations tested for the G6PD coupling reaction. 
Different color circles represent the enzymes. The combinations of enzymes tested were shown as in 
well A1 to A7. G6PD = First enzyme, 6PGL= Second enzyme, 6PGD =Third enzyme in the PPP.
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3.3.3.4.3 Coupled G6PD reaction − excess amount of the downstream enzymes
To investigate the effect of adding the excess amount of 6PGL and 6PGD enzyme in the 
reaction, different ratio of the enzyme (v/v) was added to the reaction until no enzyme was 
the limiting factor. The increase of the activity was compared to the reaction with G6PDalone. 
The reaction was executed as described above in Section 3.2.1.5.
3.3.3.5 Kinetics studies of G6PD reaction at 340 nm vs. 460 nm
The kinetics of G6PD is a bi-substrates system. Thus, two sets of measurements were 
performed where one substrate was fixed, and the other was varied and vice-versa. The range 
of concentrations used was 0.1 mM to 4 mM, and for G6P and 0.03 mM to 1.5 mM for 
NADP+. The fixed concentrations of the substrate used were 0.1, 0.25, 0.5 and 1 mM. The 
kinetic parameters of G6PD were determined by calculating the NADPH produced in the 
reaction.
The kinetics parameters for G6PD reaction at 340 nm were determined as follow: 10 μL of 
substrates − G6P and NADP+ were added individually in 96-well plates. Subsequently, a 190 
μL reaction mixture containing 100 mM Tris-HCI at pH 7.65, 10 mM MgCl2, 8 nM of 
enzyme and Milli-Q water were prepared and added last as reaction starter. The total volume 
of the reaction mixture was 200 μL and assayed at 25 °C for 3 minutes. The Km and kcat 
values were determined using Lineweaver-Burk plot and additional diagnostic plots.  
Secondary plots of the intercepts and slopes obtained from the Lineweaver-Burk against 
1/[S] to obtain the kinetic parameters following an ordered sequential mechanism.4, 5 For the 
kinetics of G6PD at 460 nm, a similar protocol as described above was applied. A similar 
concentration of NADP+ and G6P were used. 10 μL of each substrate was added individually 
to the 96 well plates. For the preparation of the enzymes, all three enzymes at an equal 
concentration of 8 nm each were added to a total of 190 μL reaction mixtures containing 100 
mM Tris-HCI at pH 7.65, 10 mM MgCl2, 0.05 mM WST-8, 0.02 mM PMS and Milli-Q 
water, which was added last as a reaction starter. The assay was performed as described for 
the G6PD reaction at 340 nm above. 
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3.4 Results
3.4.1 Protein expression, solubility, and purification of WT G6PD, 6PGL, and 6PGD
The genes for G6PD, 6PGL, and 6PGD from both E. coli and Z. mobilis were isolated with 
PCR and successfully inserted into the pETMCSIII plasmid. The constructs were sequenced 
to check that the transfer had been done correctly. The characteristics of both plasmids were 
studied to determine which gene yielded the highest expression and greatest solubility. For 
E. coli, the G6PD and 6PGD are highly expressed and mostly soluble compared to the gene 
from Z. mobilis, whereas 6PGL from Z. mobilis is slightly more soluble than the E. coli 
version (Table 3.1 and Figure 3.6). 
Table 3.1 Constructs of enzymes used in this study
Construct
Escherichia 
coli Construct
Zymomonas mobilis
E S P E S P
Glucose 6-
phosphate 
dehydrogenase 
(G6PD)
[1st enzyme]
Cloned into 
pCY76 vector and 
subcloned into 
pETMCS III
✓ ✓ ✓
Cloned into 
pET47b vector 
and subcloned 
into pHUE 
✓ X X
6-Phosphoglucono
lactonase
(6PGL)
[2nd enzyme]
Cloned into 
pET28a vector 
and subcloned 
into pHUE
✓ X X
Subcloned into 
pETMCS III ✓ ✓ ✓
6-phosphogluconate
dehydrogenase 
(6PGD)
[3rd enzyme]
Cloned into 
pET47b and 
subcloned into 
pETMCS III
✓ ✓ ✓
Cloned in 
pET28a vector 
and subcloned 
into pHUE
✓ X X
Indicator: E: Expression, S: Solubility, and P: Purification
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 24 h                  3 h                     1 h 
  S       NS S NS S NS 
97.4
66.2
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31
21.5
37 °C 25 °C
Soluble Insoluble Soluble
24h 3h 1h 0h 24h 3h 1h 0h 24h 3h 1h 0h 97.4 
66.2 
45.0 
31.0 
Soluble Insoluble
0h 1h 3h 24h 1h 3h 24h
(A) G6PDWT (B) 6PGDWT 
(C) 6PGLWT 
M
(D) (E) (F) 
Figure 3.6 Expression, purification and protein analysis of G6PDWT, 6PGLWT and 6PGDWT proteins. 
(A-C) 10-12% SDS-PAGE of proteins expression incubated at 37 °C 0.5 mM IPTG in LB medium for 
3 to 24 hours. Figure (A and B) showed the expression of G6PDWT and 6PGDWT at 37 °C, 
respectively, while (C) showed the expression of 6PGLWT at 37 °C and 25 °C  (D-F) showing the 
elution patterns of G6PDWT, 6PGLWT, and 6PGDWT proteins using a Histrap nickel column (G-I) 15% 
SDS-PAGE gel analysis of protein after column purification. The arrow indicates the target proteins 
while the first peak is for unspecific protein. Each well was loaded with 10 μL of sample. 
(NS=Insoluble, S=Soluble).
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Figure 3.6 (A-C) showed the expression of G6PDWT, 6PGLWT and 6PGDWT with induction 
of 0.5 mM IPTG at 37 °C. The maximum protein expression of G6PDWT, 6PGLWT and 
6PGDWT was obtained after 3-hour induction with 0.5 mM IPTG in LB medium at 37 °C. 
This condition was used for protein expression throughout this study. Both G6PDWT and 
6PGDWT were highly expressed. However, for 6PGLWT, the expression is slightly poor at 
both 25 °C and 37 °C. Thus, a large-scale culture was prepared to get enough volume of the 
soluble enzyme for assay. For this, 2L of 2XYT or TB media was used as culture medium 
instead of LB to increase the pellet yield and expression. Although it is less soluble 
compared to G6PD and 6PGD enzyme, only small amounts of 6PGL were required for the 
assays. 
The proteins were purified using the method in section 3.2.1.2 and the purity of the proteins 
was checked using 15% SDS-PAGE gel (Figure 3.6 G-I). The estimated molecular weight 
from the SDS-PAGE for G6PDWT, 6PGLWT, and 6PGDWT was around 55 kDa, 30 kDa and 
50 kDa, respectively. Meanwhile, the theoretical molecular weight obtained from ExPASy 
Protparam tool based on the amino acid sequences for the G6PD, 6PGL, and 6PGD was 57.5 
kDa, 27.3 kDa and 51.5 kDa, respectively. These values were similar to the observed. In this 
study, the 6PGD and 6PGL enzymes were not the main protein of interest and details of the 
enzymes have been reported elsewhere.6, 7 No further works to characterize the enzymes was 
performed. The purified protein was kept in 50% glycerol and kept at -20 °C to preserve the 
activity.
3.4.2 Colorimetric G6PD enzyme assay using WST-8/PMS and DCPIP/PMS
3.4.2.1 Optimization of assay parameters  
The G6PD assay with WST-8/PMS and DCPIP/PMS is expected to exhibit higher 
sensitivity, as compared to assay at 340 nm. Therefore, parameters like the concentration of 
WST-8, PMS, NADP+, and G6P were optimized. Figure 3.7 (A) showed the initial assay 
conditions applied at higher concentrations of substrates and coupling reagents. At saturating 
levels of substrates, the observed reaction profile was not linear. At high concentrations of 
reagents used the absorbance started at 0.8 and reached 2 after 1 minute of reaction time. The 
range of the absorbance was too high and might not be reliable as the detection limit of 
absorbance for the plate reader was around 2. The assay was also deemed too expensive. 
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Figure 3.7 Effect of parameters on the reduction of WST-8 by E. coli G6PD enzyme. Changes of 
absorbance for time course G6PD reaction was plotted against the various concentrations of 
parameters tested. Formazans produced by G6PD enzyme was measured at 460 nm with a plate 
reader.
(A) The initial condition used saturating concentrations of reagents: 0.25 mM G6P, 0.25 mM 
NADP+, 0.5 mM PMS, and1 mM WST-8.
(A1) The concentrations of substrates were reduced to 0.1 mM G6P and 0.1 mM NADP+ (red     
       dotted line) or 0.05 mM G6P and 0.01 mM NADP+ (blue dotted line).
(A2) With 0.5 mM WST-8, the coupling reagent, PMS was tested at 0.05 mM (red dotted line)    
       or 0.02 mM PMS (blue dotted line).
(A3) The optimized assay condition was at 0.05 mM G6P, 0.01 mM NADP+, 0.02 mM PMS, 
        0.5 mM WST-8. The assay was run at 25 °C for 90 seconds.
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Subsequently, the concentration of substrates (G6P and NADP+), was adjusted below the 
published Km values of 0.015 mM for NADP+ and 0.070 mM for G6P.8 At the adjusted 
concentrations of substrates, a linear slope was obtained. However, at 0.1 mM NADP+ and 
G6P, the linear range falls within absorbance of 0.65 to 0.9, which is still high (Figure 3.7, 
A1). While at 0.05 mM G6P and 0.01 mM NADP+, the linear absorbance is within 0.64 to 
0.7 but the slope is not steep (Figure 3.7, A2). Then, the concentration of the coupling 
reagents, WST-8 and PMS was adjusted until 0.02 mM PMS and 0.5 mM WST-8. At this 
concentration, the absorbance started at 0.15 and produced a steep and linear slope up to 3 
minutes of reaction time (Figure 3.7, A3). Only 0.02 mM PMS and 0.5 mM WST-8 is 
required to turnover the NADP+/NADPH in the reaction. Thus, the final assay condition was 
set at 0.1 M Tris-HCI pH 7.65, 10 mM MgCl2, 0.05 mM G6P, 0.01 mM NADP+, 0.02 mM 
PMS and 0.5 mM WST-8. 
Finally, based on the relative activity results we conclude that WST-8/PMS is a better and 
more sensitive dye to detect the G6PD enzyme activity compared to DCPIP. Although low 
concentrations of parameters were employed in the optimized assay conditions, it is still 
sensitive and produced a satisfactory signal for detection of G6PD activity. Thus I concluded 
that this condition was ideal for detecting E. coli G6PD and was also economical. Besides, 
the solubility of DCPIP also contributes to the decision. DCPIP is less soluble in water. For 
dissolving, the buffer or Milli-Q water needs to be pre-heated at 50 °C prior, and this adds 
extra steps to the assay. In contrast, WST-8 tetrazolium salt has high solubility in water and 
is also reported to be more stable.2 Hence, throughout this project, the WST-8/PMS system 
was used for detection of G6PD enzyme activity unless otherwise stated.
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3.4.2.2   Validation of optimized assay condition
To validate the optimized conditions, time course assays for E. coli G6PD enzymes were 
performed for 3 minutes using the WST-8/PMS or DCPIP/PMS coupling systems at 460 nm 
and 600 nm, respectively. The results of the optimized assay conditions are shown in Figure 
3.8 below. The slope produced at this condition was linear up to 3 minutes reaction time. 
Herein, we conclude that this condition is suitable for determination of E. coli G6PD 
activity.
     (A1)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0:00 0:50 1:40 2:30 3:20
G6PD
G6PD + 6PGL
G6PD + 6PGL + 6PGD
6PGL
6PGL + 6PGD
6PGD
6PGD + G6PD
Ab
so
rb
an
ce
(4
60
nm
)
Time (min)
    (A2)
0.5
0.6
0.7
0.8
0.9
1
1.1
1.2
0:00 0:50 1:40 2:30 3:20
G6PD
G6PD + 6PGL
G6PD + 6PGL + 6PGD
6PGL
6PGD
6PGL + 6PGD
6PGD + G6PD
A
bs
or
ba
nc
e
(6
00
nm
)
Time (min)
Figure 3.8 Absorbance rate of G6PD reaction with WST-8/PMS and DCPIP/PMS using final assay 
condition. (A1) Reaction with WST-8/PMS (A2) Reaction with DCPIP/PMS. The final conditions used 
contains 100 mM Tris-HCI buffer pH 6.5, 10 mM Mg2+, 0.5 mM WST-8/DCPIP, 0.02 mM PMS, 0.010 
NADP+, 0.050 G6P and 0.15 μM of enzyme. A linear slope between 30 seconds to 150 seconds was 
used to measure the activity.
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3.4.2.3 A “lag phase” occurs in reaction with WST-8/PMS
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Figure 3.9 The “lag phase” observed in the time course reaction of G6PD with WST-8/PMS. 
Magnification of Figure B1 showing the “lag phase” (blue arrow). The final conditions used contains 
100 mM Tris- buffer pH 6.5, 10 mM Mg2+, 0.5 mM WST-8/DCPIP, 0.02 mM PMS, 0.010 NADP+, 
0.050 G6P and 0.15 μM of enzyme.
As shown in Figure 3.9, a “lag phase’ was observed in G6PD reaction with the dye. This 
phenomenon was not observed in the G6PD reaction with no dye. The traces of the reaction 
become linear after 10 seconds. This condition might be due to equilibrium between the 
mixtures containing the dye. The dye might require a certain second to mix homogenously. 
Thus, the lag phase can be minimized or eliminated by adjusting the concentration of 
enzymes. Nevertheless, the lags did not interfere with the reaction because only linear slope 
of the reaction within the first 2 minutes (after the lag phase) were taken for measurement of 
the activity. 
3.4.3   G6PD couple reaction with two downstream enzymes in PPP
3.4.3.1 Equal amounts of enzymes 
In this assay, equal ratios of enzymes (1:1:1) were used to determine the effect of the 
downstream enzymes to the G6PD activity. The effect on G6PD activity was carefully 
analyzed by a time-course reaction at 25 °C in 96-well plates. The G6PD activity was then 
compared between assay at 340 nm (no dye) and with dyes, expressed as the relative 
activity. In this study, two dyes: WST-8 and DCPIP were used with the electron carrier, 
PMS to compare the productivity of the dyes to the G6PD reaction.  Coupling reaction of 
G6PD with WST-8/PMS generated NADPH that will convert the tetrazolium salt WST-8 to 
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produced an orange colour formazans at 460 nm. While, with DCPIP/PMS, the NADPH 
generated will reduce the blue colour of DCPIP to colourless at 600 nm. The colour changes 
were shown in Figure 3.10, and the G6PD activity of the coupling reaction was shown in 
Figure 3.11.
Figure 3.10 Colour changes in G6PD reaction with WST-
8/PMS and DCPIP/PMS. The image of wells from 96-well 
plates shows the appearance of reaction mixtures after 
incubation at 25 °C for 180 seconds as in Figure 3.8.The 
intensity of the color change depends on the G6PD 
activity. (G6PD:1st enzyme in the PPP; 6PGL; 2nd 
enzyme, 6PGD: 3rd enzyme).
According to the results shown in Figure 3.11, only minor improvement was noticed in 
G6PD activity at 340 nm upon addition of 6PGL and 6PGD in the reaction − the 
improvement was about 1.2 fold and 1.4 fold, respectively. As for DCPIP/PMS, the 
improvement observed was similar to reaction at 340 nm. However, the assay with WST-8 at 
460 nm showed better improvement. Upon the addition of the 6PGL, the initial rate of 
reaction increased by almost 1.3 fold compared with G6PDalone. Meanwhile, addition of the 
second and third downstream enzyme − the 6PGL and 6PGD, to the G6PD increased the 
reaction by 1.7 fold. The increments showed that the contribution of the two downstream 
enzymes was to cause the reaction to go faster. The addition of the downstream enzymes was 
to eliminate the products of the reaction faster and increase the amount of product formed. 
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Figure 3.11 Coupling assay of G6PD enzyme activity with the downstream enzymes. The enzyme 
reaction was measured using the wavelength indicated and the enzyme activity was calculated 
relative to the activity of G6PDalone. The reaction rate was measured at 25 °C for 180 seconds. The x-
axis displayed the combinations of enzymes tested. (G6PD: 1st enzyme in the PPP; 6PGL; 2nd 
enzyme, 6PGD: 3rd enzyme).
However, the relative activities between the G6PD + 6PGL and G6PD + 6PGD were similar. 
It was predicted that adding the 6PGL will degrade the product of G6PD reaction faster and 
improve the reaction compared with G6PDalone. But, that was not the case in this study; this 
might be due to rapid hydrolysis of the lactone. The 6-phosphogluconolactone is prone to 
hydrolysis.9 The results suggest that G6PD is more limited by NADPH accumulation. 
Without NADPH oxidation by PMS, then there was a slight improvement when 6PGL 
added. Whereas, with PMS and dye, there is no significant improvement as the major 
limitation (NADPH accumulation) is dealt with. Nevertheless, minimal or no activity was 
detected in reactions without G6PD. This emphasizes the role of G6PD enzymes as the rate-
limiting enzyme in the PPP. The results proved the importance of the two downstream 
enzymes to increase the sensitivity of G6PD reaction as mentioned in Section 3.1.2. 
However, only a low level of activity was observed in the 6PGL + 6PGD reaction. This 
reaction was supposed not to have any activity as no G6PD enzyme added. This might not 
just reflect the error level of the assay or perhaps some contamination of 6-phosphogluconate 
(6PG) in the G6P stock.
59
3.4.3.2 Excess of the downstream enzymes
From the excess of downstream enzymes assay, adding two times volume of 6PGL increased 
the G6PD reaction by 2.5 fold (Figure 3.12A).  Meanwhile, adding 11 times an excess 
volume of 6PGD increased the reaction up to nearly four-fold (Figure 3.12B). However, the 
results shown were not as predicted − only two times the volume of 6PGL required for the 
reaction. It was predicted that excess volume of the 6PGL was required to remove the 
product of reaction faster. The addition of the extra volume of 6PGL to the G6PD reaction 
only gave a slight difference compared with the rate with 1:1:1 ratio. The result suggested 
that extra 6PGL is unnecessary because the enzyme is not rate limiting. More likely, the 
excess volume of the third enzyme (6PGD) in the pathway helps to compensate the 6PGL 
activity and drags the reaction faster to completion. Nevertheless, addition of the excess 
volume of the subsequent enzymes did increase the G6PD reaction rate. 
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Figure 3.12 Optimization of the G6PD couple reaction with excess amounts of the downstream 
enzymes. (A) Excess of 6PGL (B) Excess of 6PGD. The initial activity of the reaction was measured 
spectrophotometrically at 460 nm. The initial activity of the reaction was reported as the relative 
activity to the G6PDalone.
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From work described in the previous section (Section 3.4.3.1), it was clear that the addition 
of the downstream enzymes has a small but detectable influence on activity and that the 
background activity (in the absence of G6PD) was at the level of the errors in the 
experiment. However, low levels of the downstream enzymes gave activity levels that 
reflected their activity as well as that of G6PD. Vast excess of the two downstream enzymes 
was required to rapidly removed products so that the observed activity reflected that of 
G6PD.
Activity was measured as a function of the concentration of the two downstream enzymes as 
shown in Figure 3.12. Relatively, small increase in the concentration of the 6PGL gave 
saturating levels of activity, while the concentration of 6PGD required is 11-fold increase. It 
appeared that a two-fold and 11-fold increase in 6PGL and 6PGD respectively gave 
saturating levels of activity that reflected the activity of G6PD.
3.4.4 Sensitivity of the G6PD coupled assay at low substrate concentration
To determine the sensitivity range of the coupled assay for G6PD with WST-8/PMS and in 
the presence of excess 6PGL and 6PGD, several tests were conducted, and the signal 
produced was recorded. In this study, G6P was tested at 0.005, 0.01, 0.02, or 0.04 mM 
(below 0.05 mM, the concentration used for assay in the study) and NADP+ at 0.005, 0.01, 
or 0.02 mM in 96-well plates. The results showed that using the conventional assay at 340 
nm (no dye), the signal for the G6PD reaction was almost undetectable within the range of 
substrates tested (Figure 3.13). The background noise was too high during the 
measurements. At 8 nM of final G6PD enzyme used, the reaction required > 0.04 mM G6P 
and > 0.02 mM NADP+ or higher to produce a detectable signal. Hence, the assay was not 
sensitive at low substrate concentrations. 
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Figure 3.13 The detection limit of G6PD assay tested at different concentrations of substrates at 340 
nm and 460 nm. The detection limit was determined as the concentration that able to produce a 
linear slope of activity with no background noise. The time-course assay was performed for 3 minutes 
in FB 96-well plates at 8 nM of final enzyme concentration for G6PD (340 nm) and 460 nm and 2 nM 
for reaction with excess 6PGL and 6PGD. (n=2).
However, the signal increased when the G6PD reaction incorporated WST-8/PMS. The 
sensitivity of the G6PD reaction was easily detected at ≥ 0.01 mM concentrations of both 
G6P and NADP+. The sensitivity of the reaction was further increased when the G6PD was 
coupled with the excess volume of the downstream enzymes, 6PGL and 6PGD. The lowest 
substrates detectable for the G6PD reaction were ≥ 0.005 mM NADP+ and ≥ 0.05 mM G6P. 
In this assay, the sensitivity for NADP+ and G6P increased by two and four fold respectively, 
in comparison to the assay of G6PD alone at 460 nm. When directly compared to G6PD 
reaction at 340 nm (no WST-8/PMS), the sensitivity improved tremendously. Although the 
sensitivity of the reaction was enzyme concentration dependent, the results clearly 
demonstrated that assays with WST-8/PMS and excess enzymes provide a better signal, with 
the sensitivity of assay as low as 0.005 mM for both NADP+ and G6P − hence a more 
sensitive assay system for G6PD. 
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3.4.5 Kinetics measurements of G6PD-coupled reactions 
The Lineweaver-Burk plots shown in Figure 3.14 were constructed to determine the kinetic 
parameters of G6PD reaction that used G6P and NADP+ as substrates.4, 5 The data are 
displayed using a linear graph to simplify the interpretation of the results − the studies of 
G6PD reaction is a bi-substrates system that required a different combination of NADP+, and 
G6P tested. For an easier comparison, the parameters were divided into two groups; no dye 
(340 nm) and with dye WST-8/PMS (460 nm). The kinetic parameters of the two groups 
were directly compared to the reaction with G6PDalone at 340 nm (no dye).   
Figure 3.14 Lineweaver-Burk plots for the wild-type G6PD reaction monitored at 340 nm. (A) Primary 
plots of 1/v against 1/ [NADP+] at various concentrations of G6P. (B) Secondary plot of intercepts of 
primary plots against 1/[G6P]. (C) Secondary plot of slopes of primary plots against 1/[G6P]. The 
same procedures were applied for NADP+ as the hold substrate. The assays were performed at pH 
7.65 in triplicate at 25 °C. 
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For kinetics reaction with no dye, the Km for G6P of 0.42 mM was obtained with G6PDalone 
reaction (Table 3.2). The Km value differs slightly from the published values for E. coli 
G6PD due to differences in methodology used, such as enzyme preparation and 
concentration of substrates used. While for NADP+, the Km value was 0.06, which is in line 
with the reported values.8, 10, 11 The E. coli G6PDWT has a relatively low affinity for G6P 
compared with NADP+. The kcat for the reaction was 146 s-1 which, is also comparable to the 
reported values.10, 11 
Table 3.2 Kinetics parameters of G6PD reactions in absence and presence of WST-8
Reaction kcat (s-1) Km G6P
(mM)
Km NADP+
(mM)
No dye (340 nm)
G6PD alone 146 ± 7 0.42 ± 0.1 0.06 ± 0.03
With dye: WST-8/PMS 
(460 nm)
G6PD alone 619 ± 125 (4.2) 0.2 ± 0.03 0.02 ± 0.01
Coupled reaction
(G6PD: 6PGL: 6PGD) 1:2:11 1137 ± 214 (7.8) 0.1 ± 0.01 0.02 ± 0.01
For G6PD reaction with the downstream enzymes, the kcat values were divided by 2 mol of NADPH 
produced per G6PD reaction. The steady-state parameters were determined in 0.1 M Tris-HCI buffer 
with 10 mM MgCl2 at pH 6.5, 0.01 mM NADP+, 0.05 mM G6P at 25 °C (340 nm for no dye) and with 
addition of 0.02 mM PMS and 0.5 mM WST-8 for reaction with dye (460 nm). Values in parentheses 
represented the fold kcat increase over the G6PDalone at 340 nm reactions. The extinction coefficient of 
NADPH obtained from plate reader is 2455 M-1cm-1. Experiments were run in triplicates. Reported 
values for kinetics of G6PDalone at 340 nm 8, 10, 11: kcat~ 87-174 s-1 , KmG6P ~ 0.07-0.2 mM, KmNADP+~ 
0.08-0.015mM.
For the kinetic reaction with WST-8/PMS, the Km values for G6P is higher than the NADP+, 
suggesting a higher affinity for NADP+, which is similar to G6PD reaction with no dye. In 
comparison with G6PDalone at 340 nm, the kcat for G6PD with WST-8/PMS at G6PDalone and 
1:2:11 increased by 4.2 fold and 7.8 fold, respectively. However, the huge standard deviation 
was noted in the reaction with WST-8/PMS although no exact reason was understood. This 
might due to mixing equilibrium required during the reaction or fitting error from graph. 
This mixing produced a slight delay in the reaction as mentioned in section 3.3.4.1. In 
conclusion, the results clearly showed that the G6PD assay with WST-8/PMS and addition 
of the subsequent enzymes − 6PGL and 6PGD increased the rate of G6PD reaction, but no 
effect on the affinity for G6P or NADP+ was observed.
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3.5 Discussion
In this study, we reported the modified colorimetric assay using WST-8/PMS and 
DCPIP/PMS for purified E. coli G6PD enzyme. Therefore, all the enzymes required in this 
study were purified using His-Trap Nickel column chromatography and were at >90% 
purity. The applications of WST-8 or DCPIP as the secondary electron acceptors, with the 
PMS in the enzyme-coupled reaction, have been reported.1, 12 Based on this study, there are 
several advantages of measuring the G6PD enzyme reaction with the colorimetric reagents 
like WST-8 and DCPIP. The present method developed offers several advantages over the 
traditional assay at 340 nm.
(I) WST-8/PMS is more sensitive and cost-effective than DCPIP/PMS. From the 
assay, WST-8/PMS is preferable over DCPIP/PMS coupling system because it is 
easier to dissolve − fewer labour works required during preparation. Besides, the 
unique property of the water-soluble tetrazolium salts to produce an intense 
orange coloured formazan product under reduction condition makes it highly 
applicable for many biochemical applications. We found that incorporating the 
WST-8/PMS to the G6PD reaction able to detect the enzyme activity using low 
substrates concentration, below the reported Km for E. coli G6PD. The reported 
Km for G6P and NADP+ was 70 μM and 15 μM, respectively.8 The high 
extinction coefficient for WST-8 formazan dye (37 000 M-1 cm-1), which is 4-6 
folds higher than NADP+ (6022 M-1 cm-1) enables low concentration of NADP+ 
required.2 In this study, only 50 μM of G6P and 10 μM of NADP+ were used for 
the assay. At this concentration, the slope of the reaction was linear for 3 minutes 
(Figure 3.12). With these conditions, the assay is economically favourable and 
sensitive enough to detect the enzyme activity using purified protein. As for field 
use, the assay may need further modification, especially when used with the 
blood sample.
(II) Increased the rate of G6PD reaction compared to detection at 340 nm. The 
addition of the excess of the subsequent enzymes in the PPP increased the rate of 
G6PD reaction by 8-fold. The excess amount of the subsequent enzymes helps to 
degrade the product of the reaction faster − the extra NADP+ reduction to 
increase the signal. As a result, it drags the reaction to the right and hence, the 
response time for the G6PD reaction decreased – time-saving. This assay might 
be a pioneer for a better development of new tools for G6PD detection. Fast 
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response time is important to develop a quick and rapid test for the G6PD 
detection.
(III) General applicability of WST-8/PMS assay for biochemical applications for 
NADPH-producing enzymes. Due to the orange colour formazan produced, 
WST-8/PMS assay system for G6PD enzyme opens a new window for 
biochemical applications for NADPH-producing enzymes. The colorimetric 
G6PD assay developed in this study could give a new insight in screening 
methods for protein engineering study. Although the assay was initially 
improvised for detecting G6PD activity using purified enzyme, the assay can be 
optimized for selection and screening of directed evolution library. Based on the 
sensitivity of the assay and the property of WST-8 that produced formazan upon 
cellular reduction, there is a possibility that this assay conditions could be 
applied for crude lysate assay. However, the details of this idea will be given in 
Chapter 4.
3.6 Conclusion
A sensitive assay for detection of G6PD enzyme activity in the laboratory has been 
developed. This assay was developed using the WST-8 dye that was sensitive and 
economically favourable as it only requires low substrate concentrations. The sensitivity of 
the assay was also significantly improved by coupling the reaction of G6PD with the other 
two downstream enzymes in the PPP. This assay condition has offered an insight into 
developing new tools for G6PD detection for the screening of recombinant library for 
protein engineering studies.
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4.1 Preamble 
 
This chapter is primarily concerned with the use of directed evolution to improve the 
stability of G6PD. The motivation for this work was to improve the enzyme for a number of 
practical applications alluded to in Chapter 1. A short description of directed evolution will 
be given in the introductory text that follows. The most difficult step in these experiments is 
the development of suitable high-throughput screens to identify enzymes with enhanced 
properties. A brief outline of these methods will also be given below. The experimental 
section of this chapter was divided into two parts. Part I will focus on the design of screening 
assays for crude lysates using the tetrazolium salt, WST-8 and the electron mediator, PMS 
(phenazine methosulfate). In Part II, the use of the assays in the directed evolution to 
increase the stability of E. coli G6PD will be described. 
 
4.2  Introduction 
4.2.1 Protein Engineering 
 
Enzymes, as they occur in nature, have evolved to satisfy the needs of their host organism. 
However, the needs of an organism are not the same as those of an industrial chemist and 
enzymes usually require modification to suit the needs of industry. There are two broad 
approaches to protein engineering: rational methods and directed evolution. In very general 
terms, rational approaches are very powerful but require prior knowledge of the targeted 
protein. They usually require a high-resolution structure to manually or computationally 
predict the changes that will yield the desirable traits. Directed evolution applies the 
³Darwinian´ concept of evolution; that is the selection of desired traits from a pool of 
randomly mutated variants. Reviews of the various approaches are available and will not be 
described here.1, 2 These reviews make it clear that there are advantages and disadvantages 
associated with each of the various approaches to engineering. After some consideration, it 
was thought that directed evolution was the best approach for modifying G6PD. G6PD is a 
large and highly regulated oligomeric protein and not well suited to rational approaches. In 
addition, there was no structure for the E. coli protein ± the preferred candidate for our 
studies. General reviews of directed evolution are also available 3, 4 as are publications that 
describe application of the various techniques.5-7 
 
In general, there are five stages in directed evolution (Figure 4.1). These are library 
generation followed by selection and/or screening to identify variants with desired traits. 
Individuals with improved traits are used to generate progeny that are also used to generate 
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future generations with improved characteristics. The process is reiterated until individuals 
with the desired traits are obtained. It should be noted that library generation simply means 
generating a pool of mutant proteins. The size of the library will depend upon the method 
used to screen the library ± there are practical limits in the resources and time available for 
screening a library. The library is generated using PCR so that mutations can be introduced 
at a known rate. The process starts with simply mutating the native gene and shuffling 
techniques to generate recombined libraries in later generations.8 These techniques have 
been described elsewhere and will not be elaborated upon here.9 The library can be screened 
or subjected to selection. Selections require that conditions are known under which the 
parents of a library are known not to survive and surviving mutants are used as the parents of 
subsequent generations.  Screening means that the activity of individual mutants is measured 
and this is used to determine the parents of the next generation. This is the method used in 
the work of this thesis. The screening process is done in two stages. The primary screen is a 
high-throughput screen where the emphasis is on rapidly measuring the activities of a large 
library í it does not always give accurate values for the activity. In the secondary screen, the 
candidates identified in the primary screen are subjected to multiple activity measurements 
to get a better estimate of their activities. The improved variants are then isolated and pooled 
as the template for the next generation. Just like this, the cycle continues until the desired 
properties are achieved and the variants obtained no longer display any improvements. 
 
 
 
 
Figure 4.1 General schemes for directed evolution 
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4.2.2 High-throughput G6PD screening assay for crude cells lysate   
 
Many of the methods used in directed evolution are routine and are applicable to most 
applications. Specifically, the methods used to generate mutant libraries are much the same 
as the properties of the DNA in various genes are much the same and respond to PCR 
treatment in much the same manner. The actual methods used to generate libraries are given 
in the next section of this chapter and no overview will be given here. However, unlike 
DNA, the properties of proteins vary greatly and the methods used to monitor their 
properties are usually very specific for the application. This chapter focuses on the method 
developed to produce a high-throughput assay G6PD and it is appropriate that some of the 
historical backgrounds for this work is given.  
 
The assay developed herein was a modification of the currently available method described 
by Tantular and Kawamoto.10 This assay involves the use of WST-8, a tetrazolium salt that 
undergoes a color change upon reduction. The WST-8 in presence of electron mediator, 
PMS rHDFWZLWK1$'3+UHGXFHGE\WKH*3'WRSURGXFHRUDQJHFRORXUHGIRUPD]DQG\Hí 
making it an ideal colorimetric assay (Figure 4.2). This method was proven effective for 
blood samples, but no account of its use with bacterial cells has been reported. Thus, this 
chapter will describe the development of protocols that use WST-8 to detect G6PD enzyme 
activity in high-throughput screens. 
 
 
 
 
Figure 4.2 Principle of the chemical reaction for WST-8/PMS assay for G6PD activity 
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The use of tetrazolium salts as tools for measuring metabolic activity has been exploited in a 
range of cell types: from mammalian to microbiological cells.2 The ability of the tetrazolium 
salts to produce a coloured formazan product upon the reaction makes it suitable for a 
colorimetric assay in various applications. These applications include measuring cell 
proliferation and antimicrobial susceptibility11. Over the past century, various tetrazolium 
salts, such WST-1, and WST-8, have been synthesized and used in cellular and clinical 
assays using spectrophotometric and fluorometric methods.12-15 Unfortunately, most of these 
tetrazolium salts have rather low solubility or produce an insoluble formazan product.11 This 
insolubility interferes with efficient detection so that a great deal of effort is required 
solubilize the compounds prior to assay. Poor solubility limits some of the applications or 
many of the tetrazolium salts. However, WST-8 was a superior tetrazolium salt in regard to 
the solubility. It produced a highly soluble formazan, hence assay with WST-8 confers fewer 
steps. In practice, the intensity of the color change observed with WST-8 was directly 
proportional to G6PD activity. As the reaction yields a strong orange color so that it is ideal 
for both qualitative observations of activity and quantitative measurements of it.  
 
In this chapter, we explore the possibility of using WST-8 for applications in engineering 
active and stable forms of G6PD variant via directed evolution. Most of the previously 
mentioned tests for G6PD deficiency used blood samples or dried blood-spotted filters.16 
None have reported the high-throughput screening method using the WST-8 in crude cell 
lysate. Herein, we describe a one-step qualitative screening method using filter paper and a 
quantitative high-throughput screening using 96-well plates by measurement of absorbance 
to detect G6PD activity in the experiments to improve the stability of G6PD. 
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4.3 Materials and Methods 
4.3.1 Materials 
 
 
The WST-8, 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H 
tetrazolium, monosodium salt was synthesized by Assoc. Prof Ross McGeary (University of 
Queensland, AU). G6P was purchased from MP Biomedicals (Seven Hills, NSW, AU). PMS 
and NADP+ were obtained from Amresco (Solon, OH, USA). Stabilized recombinant 
lysozyme solution (rLysozyme) was purchased from Sigma-Aldrich. The G6PD from E. coli 
was obtained from a stock culture of Ollis laboratory (RSC, ANU, AU).  
 
Unless otherwise stated the screening solution (Sol-A) used throughout the work described 
in this chapter was diluted as described below to give 0.05 mM G6P, 0.01 mM NADP+, 0.02 
mM PMS, 0.5 mM WST-8, 10 mM MgCl2, 100 mM Tris-HCI buffer (pH 7.65).  
 
4.3.2 Methods 
4.3.2.1 Construction of recombinant library 
 
The libraries were generated by error-prone PCR with the addition of 0.1 mM manganese 
ion used to introduce mutations to the gene. The ePCR protocol was given in section 2.5.1.  
The PCR products were run on an agarose gel and cut out for purification using Qiagen kits 
as specified by the manufacturer. Using protocols described in Chapter 2, the purified ePCR 
products were digested at NdeI and EcoRI restriction sites and ligated into the constitutive 
expression vector, S&<DQG WKHQ WUDQVIRUPHG LQWR HOHFWURFRPSHWHQW'+ĮE. coli cells. 
The mutation rate of the library was determined by sequencing 10 plasmids, at random, with 
the mutated genes. The sequencing was performed as described in section 2.4.4. 
 
4.3.2.2 Preparation of culture and lysate for assays 
 
The activity of the G6PD and evolved variants were assessed with enzyme expressed using 
the pCY76 plasmid that had been prepared by a previous student for the constitutive 
expression of target proteins.17 Cell growth and background activity of cells can be affected 
by protein expression so that a control protein with no dehydrogenase activity was chosen to 
act as a control. The gene for the enzyme dienelactone hydrolase (DLH) expressed in pCY76 
was chosen for this purpose. The cells were grown in sealable 96-well plates (round bottom):  
ȝ/ of LB media supplemented with ampicillin was placed in each well, inoculated with 
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a single colony and grown at 37 °C with agitation for 24 hours ± these were used as master 
plates. To determinH WKH FUXGH O\VDWH DFWLYLW\ ȝ/of the overnight culture from master 
plates was transferred into 96-well plates (roXQG ERWWRP DQG O\VHG ZLWK  ȝ/ RI
rLysozymeTM (Stabilized recombinant lysozyme, 10 U/mL) using microplate shaker at 
maximum speed for 15 minutes at room temperature. Lysed cells were pelleted by quick 
centrifugation prior to being assayed for activity as described below (section 4.3.2.3). 
 
Prior to screen the mutant libraries, it was necessary to determine the volume of crude lysate 
required to generate a reproducible signal for detection. Initial tests were carried out with 
varying volumes RIFUXGH O\VDWHȝ/ȝ/, DQGȝ/ With these volumes of crude 
lysate, the reaction proceeded too quickly to get an accurate value for the rate. Crude lysate 
volumes were adMXVWHGWRȝ/DQGȝ/ to obtain the best activity curves for the given 
conditions. With these volumes of crude lysate, the reaction produced a linear response for 
up to 5 minutes. $YROXPHRIȝ/of the crude lysate was used for screening the cell lysate 
as described below. At this volume, the sensitivity of the assay detection was the best. 
 
 4.3.2.3 Enzyme assay and stability screen 
 
The two methods used for the screen for stability are described below in more detail. Both 
methods give a qualitative estimate of stability so that a final and more accurate solution 
assay was required. This involves measuring the initial activity (activity with no heat 
treatment at 25 °C) of the variant followed by heat treatment. The sample was allowed to 
cool and its activity measure again. The enzyme assay and heat treatment are described 
below.  
 
)RUVFUHHQLQJHDFKȝ/ of final reaction mixtures contained ± ȝ/RIFHOO O\VDWHDQG
ȝ/ of reagent solution (Sol-A) to give a final concentration of 0.05 mM G6P, 0.01 mM 
NADP+, 0.02 mM PMS, 0.5 mM WST-8, 10 mM MgCl2, 100 mM Tris-HCI buffer (pH 
7.65). The reaction was started by adding the reagent solution to the cell lysate, and then the 
absorption at 460 nm was monitored for 5 minutes. The reaction was kept at 25 °C during 
the assay. Active mutant produces intense orange coloured formazan. Initial activity was the 
slope of the rate of the reaction taken in the linear range between the first two minutes.  
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)RU WKH VWDELOLW\ DVVD\V  ȝ/ of the lysate, as described above (section 4.3.2.2), was 
transferred into sealable plastic 96-well PCR plates for heat treatment. The sample was 
heated using the gradient function (30 to 80 °C) on a thermal cycler for 20 minutes followed 
by 5 minutes aW  &$ WUHDWHG DOLTXRW  ȝ/ZDV WKHQ WUDQVIHUUHG WR -well plates to 
determine the residual activity as described above. Thermal stability was calculated as the 
ratio of residual activity to initial activity. 
 
To arrive at a suitable heat treatment to test mutant libraries, it was necessary to determine 
the stability of the native enzyme under the conditions given in the previous paragraph. The 
results are shown below in the figure (Figure 4.3) indicate that the wild-type G6PD lost 50% 
of its activity at approximately 55 °C and approached complete heat inactivation at 60 °C. To 
enable a clear distinction between native and mutants with enhanced stabilities, 60 °C was 
used as the temperature for heat treatment in this study. At this temperature, the native 
enzyme was completely inactive while stable mutants will have remaining activity left. 
 
 
 
Figure 4.3 Temperature dependence test for the screening process. 25 °C is used as the baseline 
for activity (100% activity) and all measurements are respective to this. 
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4.4 Results and discussions 
4.4.1 High-throughput screening protocols for evolving G6PD for enhanced stability  
 
Two methods can be applied for primary screening using the colorimetric WST-8 system: (I) 
colony agar-blotting techniques and (II) solution-based assay using 96-well plates. These 
methods are shown in the figure (Figure 4.4) below: 
 
 
 
Figure 4.4 Design for thermostability evolution of G6PD 
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(I) Colony agar-blotting technique 
 
In colony agar-blotting technique, the transformed recombinant libraries were plated on 
ampicillin agar plates with approximately 100-200 colonies per plate and grown overnight at 
37 °C. Colonies were then blotted onto filter paper (Whatman) and incubated at 60 °C for 30 
minutes. After the heat treatment, the filter paper with the blotted cells was sprayed with 
reagent solution containing 0.05 mM G6P, 0.01 mM NADP+, 0.02 mM PMS, 0.5 mM WST-
8, 10 mM MgCl2, 100 mM Tris-HCI buffer (pH 7.65). The color change was qualitatively 
accessed. Active and stable colony variant will change from creamy white (initial colour of 
the blotted colony) to orange colour. Variants with greater activity and stability (residual 
activity) stained the fastest.  
 
The orange color of the formazan produced by the aerosol sprayed of the filter paper can be 
seen in Figure 4.5. However, it was difficult to distinguish the color intensity on filter paper 
because of the NADP+ recycling condition caused the colonies to turn orange after 10 
minutes.  Larger quantities of WST-8 dye could be used to improve the detection sensitivity 
(for better contrast) but the cost made this impractical. The more active colonies stained the 
fastest. For this reason, the colonies were picked based on the speed with which color 
developed. The native G6PD filter paper developed orange color after 1-2 minutes, whereas 
no colour changes were detected in control DLH filter paper. Despite obvious shortcomings 
in the assay, a significant number of positive mutants were obtained in the first three rounds 
and false positives were eliminated in the secondary screen. For future work, it would be 
useful to reduce the activity in the population: either incubate at a higher temperature, for a 
longer time or use a vector with lower expression. 
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Figure 4.5 Qualitative analysis of the G6PD stability using WST-8 screening protocols. Colony 
blotted filter paper of G6PD recombinant library was heated at the elevated temperature for 30 
minutes and sprayed with reagent solution (0.05 mM G6P, 0.01 mM NADP+, 0.02 mM PMS, 0.5 mM 
WST-8, 10 mM MgCl2, 100 mM Tris-HCI buffer at pH 7.65. Orange coloured colonies indicate active 
and stable variants. Inactive and less stable variants were showed in faint orange and yellowish.  
 
 
The corresponding variants were then selected from the original plates, inoculated 
individually into 96-well plates and grown overnight at 37 °C before being subjected to 
quantitative measurement in secondary screening. In secondary screening, the overnight 
culture from the primary screening was lysed as described in section (4.3.2.2) and the 
residual activity of the cells was measured as above (see section 4.3.2.3). The potential hits 
with improved stability were isolated from the master plates and sequenced before pooled as 
templates for the next round of evolution.  
 
(II) A solution-based assay using 96-well plates. 
 
In 96-well plates assays, the transformed recombinant library was diluted with LB media 
(supplemented with ampicillin) to give an average of three colony forming unit in each well 
(3cfu/well). The diluted recombinant library was then grown overnight at 37 °C as described 
previously (section 4.3.2.2) and subjected to quantitative measurement via microplate reader 
as in section 4.3.2.3. The protocols for screening using microtitre plate was described in 
details by Stevenson et al.9 Despite the disadvantages in terms of library size to be screened 
when compared to the colony agar blotting technique, solution-based screening is time- 
saving and give a direct measurement of the enzyme activity and the stability. Whereas, the 
colony agar-blotting technique only gives a subjective response that based on the colour 
 
 
 
Active and 
stable 
colonies Thermolabile 
and inactive 
colonies 
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change observed by the naked eye; intense orange, indicates active and stable variants, or 
faint orange or yellowish, indicates less active and stable variants. 
 
The corresponding wells that produced better stability were subjected to secondary 
screening. For this, the corresponding well was streaked on an agar plate and six individual 
clones were inoculated into 96-well plates (round bottom) í master plates. This step ensures 
that the active and stable clones were isolated. The clones were then grown and assayed as 
described in section 4.3.2.2 and 4.3.2.3, respectively. The potential hits with improved 
stability were isolated from the master plates and sequenced before pooled as templates for 
the next round of evolution.  
 
4.4.2 Quantitative measurement 
 
 
After three rounds of high throughput screening with filter papers, it was noted most of the 
progeny gave indistinguishable responses to the assay. At this point, it was decided to 
develop a solution-based assay with 96-well plates. Such an assay would only allow smaller 
libraries to be screened (in the order of thousands, rather than tens of thousands). This type 
of screen had been used by other students in the laboratory.18, 19 The approach used by other 
laboratories was to plate out libraries and then transfer a single colony to the well of a plate. 
This was extremely laborious and time-consuming. The approach taken in the lab was to 
grow up a library in solution, to determine the concentration of the cells in the solution and 
to add sufficient volume of the library to individual well so that there was an average of 3 
colonies per well. Mutants with enhanced activity were easily detected against the 
background signal of cells with normal activity. The clones responsible for the enhanced 
activity were identified in a secondary screen. The details and justification for this approach 
have been described elsewhere.9 Figure 4.6 illustrates the specificity of the screening method 
to determine G6PD activity. No activity was detected with DLH crude cell lysate (negative 
control) í only background absorption was observed, which was approximately 50 times 
lower than the values for native G6PD activity detected by the spectrophotometer. This 
showed that the WST-8/PMS is specific to dehydrogenases only.   
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Figure 4.6 The specificity of WST-8/PMS screening conditions. 
 (I) (1) Reagent solutions containing NADP+, G6P, PMS, WST-8, buffer without G6PD (2) Reagent 
solutions with G6PD produced maximal absorbance at 460 nm (3) Reagent solution with DLH. 
 (II) Aliquots RIȝ/ of E. coli crude lysate was mixed with reagent solutions (0.05 mM G6P, 0.01 
mM NADP+, 0.02 mM PMS, 0.5 mM WST-8, 10 mM MgCl2, 100 mM Tris-HCI buffer pH 7.65) and the 
initial velocity of the reaction was measured at 460 nm for 2 minutes. The figure showed the initial 
velocity recorded. 
 
 
Methods to quantify 6-phosphogluconate dehydrogenase (6PGD) activity in crude lysates 
had been developed by other workers. Their colorimetric assay used NBT (Nitroblue 
tetrazolium) /PMS to enable the detection of NADPH at low concentration.20 It was decided 
to not to use this method as the conditions for routine assays had already been determined for 
WST-8 as described in section (4.3.2.3) given above.  
 
In this study, the use of WST-8/PMS in screening gives advantages in term of solubility and 
simplicity over NBT/PMS assay. Unlike WST-8, which form highly water-soluble orange 
formazan upon the reaction, the NBT form insoluble product when reduced. This insoluble 
formazan can easily aggregate and precipitate in the assay solution after or during the 
reaction, which heavily affects the analysis í false positive. For this, an extra step for the 
assay is required to solubilize the formazan. A study to quantify the dehydrogenase activity 
in crude cell lysate using NBT/PMS added gelatin to the assay buffer to prevent precipitation 
of the insoluble formazan produced.20 Hence, in this study, the WST-8 assay can be read 
directly with no additional step required. 
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We found that the WST-8/PMS assay to be reproducibly consistent in bacterial cells grown 
and assayed using 96-well plates. For this, native cells were grown up in all the wells of 
single 96-well plates and the initial activities of individual clones (no heat treatment) were 
measured. The plates containing the native cells showed consistency across the wells with a 
coefficient of variation (CV: the ratio of standard deviation to mean) of 16-21%. The CV 
values were higher than recommended value for evaluating a screen in 96-well plates, which 
is less than 10%.7 
 
The CV value in measuring activities in 96-well plates was not that small, but it was 
sufficient for the objectives of this project ± that is thermal stability. If we were interested in 
evolving for increased activity, then the assay would not have been very useful as it would 
only have been capable of finding mutants with much enhanced activity ± and this was not 
common in our studies. However, it was noted that heat treatment caused a large drop in 
activity that was easily measured with the assay.  
 
 
4.4.3 Directed evolution of G6PD for enhanced thermostability 
 
 
Four rounds of evolution were completed in this study and the results summarized in Table 
4.1 below. The agar-blotting technique was used in the first three rounds while the solution-
based was used in the fourth. Although the agar-blotting technique produced large libraries 
to be screened, only the moderate sized libraries were screened due to the limited supply of 
WST-8. In an attempt to accelerate the rate of evolution, the mutation rate was increased to 
used values above those normally considered appropriate for directed evolution±that is, only 
1 or 2 changes per gene.7 
 
Table 4.1 Details of directed evolution of E. coli G6PD for improved stability 
Generation Primary/secondary screening Average 
mutations rate 
per gene 
 
Colony 
 
Screening mode 
1 80000/1200 CAB/96 -well plates 3.3 
2 60000/800 CAB/96 -well plates 3.8 
3 60000/500 CAB/96 -well plates 4.0 
4 6000/200 96 -well plates/ 96- well plates 5.3 
The thermal stability was measured by the ratio of residual activity (heated at 60 °C for 20 minutes) to 
initial activity. CAB = colony agar blotting technique. 
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For the first round, a library of 80,000 colonies was screened with around 400 agar plates 
that had approximately 200 colonies per plates. An average of 3 colonies per agar plates that 
stained the brightest after heat treatment were picked for secondary screening. From these 
plates, 1200 colonies were chosen for secondary screening with 1 cfu/well subjected to heat 
treatment. Twenty clones with significantly better thermostability than the native enzyme 
were selected as parents for the next generation. The native enzyme was completely 
inactivated by the heat treatment (60 °C for 20 minutes) whereas the selected variants 
retained an average of 26 ± 12% original activity. These 20 candidates were sequenced and 
15 unique sequences were obtained (see Table 4.2). Thus a total of 15 genes and the native 
gene were used to generate the next round of mutants using the StEP-ePCR method.  
 
The second round 60,000 colonies were screened and 800 clones were subjected for 
secondary screening. Many of the clones identified in the secondary screen were duplicates 
or even triplicates. In this round, the variants retained an average of 50 ± 17% original 
activity after the heat treatment. Finally, the genes for eight clones were selected as 
templates generate the library for the next round screening. Similar results were obtained for 
the third round of screening. There were about 60,000 colonies screened with only 500 
rescreened and of these eight improved variants were finally isolated. In this round, the 
average activity retained was slightly decreased to 39 ± 10%. The result might reflect the 
small library size screened with a higher incidence of repeated sequences observed. 
However, a few variants with great stability were obtained, approximately 2 fold higher than 
the mean stability ± > 70% stability. At this point, it was concluded that screening blotted 
colonies was no longer able to differentiate between parental stability and improved stability. 
Thus, 96-well agar plates screening at 3cfu/well was attempted for the fourth round. 
 
Finally, for the fourth round, the smallest library was generated with a higher mutation rate 
than previous rounds. It was screened with the solution-based technique. Approximately 
6,000 individual variants were screened. They were grown in 2,000 wells (about 22 plates) 
with 3 colonies per well. The primary screen yielded wells of variants with thermostability 
ranging from 75 to 94%. Out of this screen, only 100 variants (100 individual wells) with 
80% and above stability were rescreened and these yielded nine improved variants. Although 
it was the smallest library that had been screened, it gave the best improvements in stability 
with an average stability of 90 ± 5%. It was noted that a small number of wells appeared to 
produce more stable clones for which it was not possible to isolate DNA for sequencing. It 
was not clear why this occurred. However, most of the clones with enhanced activity could 
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be characterized. From the sequences shown in Table 4.2, it appears that the evolution may 
have yet to converge as several new mutations appeared.  
 
In this directed evolution study, the main interest was to find thermostable variants. 
However, the relative activity of the variants observed was higher than the native activity í 
given the relative activity is 1 (Figure 4.7). Hence, a cut-off relative activity value above 1 
was applied for the thermostability screening. Any variant with relative activity less than 1 
was discarded. This was to ensure that, the variants selected for thermostability also retained 
high activity. However, the crude lysate activity may not best to represent the purified 
enzyme activity in which we were more interested.  
 
 
Figure 4.7 Characteristic of the recombinant library of directed evolution under study. Values 
represented the mean values. The relative initial activity was measured at 25 °C (no heat treatment) 
and the stability was calculated as ratio of residual activity after heated over initial activity. The 
G6PDWT was completely inactive after treated at 60 °C for 20 minutes in the thermocycler. 
 
Even though the mean activity of the variants still higher than the native enzyme, the enzyme 
³trade-off´ pattern was observed as the generation continued (Figure 4.7). The activity 
decreased as the resistance to thermal denaturation increased. For the first three rounds, as 
the enzyme became gradually resistant to thermal denaturation, the initial activity decreased 
tremendously. It was only later in the fourth round that the activity recovered along with the 
sharp increased in thermostability. The additional mutations accumulated up to the fourth 
rounds, may contribute to increasing in both thermostability and activity.  
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The graph in Figure 4.7 also illustrates the improvements of the stability gained through the 
evolutions. In the first round, the mean thermal stability of the variants was 25.87% and the 
stability nearly doubled in the second round. There was a slight decrease in the stability 
obtained was observed in the third round. This may be due to insufficient size of the library 
screened í a few with higher than the mean stability was obtained. However, the mean 
stability reached 90% in the fourth round and variants with sufficient thermostability had 
been obtained for characterization. The results showed that the screening protocols for 
thermostability implied in this study, effectively generated thermostable variants worth for 
further characterization. 
 
The sequences of variants obtained in the four rounds of evolution are given in Table 4.2 
below. Variants marked with the symbol (ღ) were selected for further study. The variants 
selected had the highest thermal stability compared with other variants in each round. The 
thermal stability of the selected variants was compared with the mean stability of the variants 
in that particular generation (Figure 4.8).  
 
 
 
Figure 4.8 Thermostability of the variants selected for further characterization. The stability was 
calculated as the ratio of residual activity after heated over initial activity. The average evolution 
stability represented the stability of variants obtained from that particular evolution. 
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The graph above showed that the selected variants have the highest stability in each 
particular round of evolution. For the first round, the remaining activity increased from zero 
for native to 25%. The variants from the first round were not characterized because the 
improvements were greater in subsequent generations. The thermal stability increased by 
almost 3 fold in the second and third round of evolution. The #2-12 and #3-44 variants were 
selected for further characterization. The two variants have almost 1.5 and 1.9 fold higher 
stability compared to other variants obtained in that particular round. Finally, the thermal 
stability reached a mean stability of approximately 90%. In the fourth round, most of the 
variants obtained have the thermal stability of approximately 80 to 90%. Because of this, the 
variants with the highest thermal stability í 7,11F and 2,2G were chosen for further 
characterization. The detailed characterizations of the improved variants, as well as the 
location of the mutations, are discussed in Chapter 5. 
 
Looking at the mutations in Table 4.2, the evolution may have yet to converged as several 
new mutations appeared in the subsequent rounds. However, the mean thermal stability 
obtained, as in the fourth round of evolution was 90%  almost all variants were completely 
thermostable at 60 °C for 20 minutes. Hence, different screening pressure should be applied 
to the next generation. Screening at above 60 °C (65-70 °C) can be performed to obtain far 
better improved variants. 
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Residue 45 64 71 86 117 126 128 141 164 186 236 238 240 246 249 253 254 255 276 281 284 298 318 353 354 356 361 366 371 388 401 416 428 480 485 486
Native D E K L F A C A G N I N L M M S D L R E V V A K T E K D K N I H T I R S
Gen 1
# 1-1 I V C
# 1-2 G I V C
# 1-3 T A
# 1-4 V V C
# 1-5 R V C
# 1-6 I V C
# 1-10 S C V
# 1-11 I K I V C
# 1-12 S C
# 1-13 P I V C
# 1-14 V C
# 1-15 I A C
# 1-17 L T V C
# 1-18 G E L S I V C
# 1-20 V C
Gen 2
#2-1 V A C
#2-5 E V C
#2-9 G E L S I V C
#2-12 T A
#2-14 V I V C
#2-15 S I V C
#2-18 T V A
#2-24 I K V C
#2-26
Table 4.2 Mutations of G6PD directed evolution for enhanced stability
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Residue 45 64 71 86 117 126 128 141 164 186 236 238 240 246 249 253 254 255 276 281 284 298 318 353 354 356 361 366 371 388 401 416 428 480 485 486
Native D E K L F A C A G N I N L M M S D L R E V V A K T E K D K N I H T I R S
Gen 3
#3-26 S V T C
#3-27 I K E V A C
#3-28 V T A C
#3-35 A C
#3-39 S V T V C
#3-40 T V C P
#3-42 T V C
#3-44 T V V R C
Gen 4
1, 2A T V V R A
2, 2G T G V V R A C
2, 10A T N V V R
7, 11F T V V R
11, 5A T R T C
15, 10A S S T V V R A
11, 1G T R A
16, 1A V T G V R
18, 4A T S V E V R A C
Table 4.2 (continue) Mutations of G6PD directed evolution for enhanced stability
Residues in bold represented the prominent residues occurred in the directed evolution. Only variants marked with (  ) were further
characterized as in Chapter 5. Variants selected have the highest stability in each particular generation.
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4.5 Conclusion
The results obtained to date indicated that the methods developed herein gave rise to variants 
that exhibited increased stability. The agar blotting method provides rapid and large library 
size for screening, whereas solution based screening in 96-well plates gives an advantage of 
lysing the culture cells and selecting variant under defined condition. In this study, the first 
method that utilized agar plates was no longer useful as it was not sensitive to changes in 
stability of the evolved mutants. The second method – solution based using 96-well plates, 
needed some modification before further rounds were carried out. It was thought a longer 
heat treatment at a higher temperature would be required to obtain variants with further 
improvements. However, there was insufficient time to continue further with directed 
evolution and it was thought better to focus on characterizing the current mutant proteins. 
There was some concern that the increased stabilities obtained with crude lysates would not 
be reflected in the stabilities of mutant proteins. In other words, it was feared that the protein 
may have evolved to have improved stability within the cell or cell lysate, but not as a 
purified protein. Further, assuming that the isolated proteins exhibited improved stability, it 
was thought desirable to determine the extent of improvement and try and understand how 
this improvement came about. 
In summary, methods to evolve G6PD have been worked, but more rounds of evolution 
could be carried out to obtain further improvements.  Characterizations of the mutants are 
described in the subsequent chapters. 
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CHAPTER 5
Functional studies of E. coli G6PD
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5.1 Preamble
This chapter describes the characterization of a selection of variant forms of E. coli G6PD 
that were evolved for enhanced stability as described in Chapter 4. Very little 
characterization was done up to this point. The time left to complete this research was 
limited by the tenure of a Ph.D. scholarship. Should evolution be continued or should a 
selection of the variants obtained to-date be characterized more carefully?. Cycles of 
evolution can be tedious and carried out in a relatively time consuming, while 
characterization provides better analysis of the variants. However, the stability 
measurements were done with crude lysates and these measurements cannot monitor a 
number of factors that are important for evolution; like an expression, solubility and 
enzymatic activity. It was also thought important that the purified enzyme be examined to 
ensure that the evolution did not require some cellular component that would be lost when 
the protein was purified. G6PD variants were identified on the basis of their thermal stability 
and this is clearly the most important property to be examined. Native G6PD has been 
included in this study to provide a reference point. 
5.2 Introduction
As noted in Chapter 1, Glucose-6-phosphate dehydrogenase (G6PD) is a key enzyme in the 
pentose phosphate pathway that catalyzes the conversion of glucose-6-phosphate to 6-
phosphoglucolactone with concomitant reduction of coenzyme NADP+ to NADPH. The 
enzyme is highly regulated through a number of processes some of which involve a change 
in oligomeric structure of the protein. Stability may influence the oligomeric structure of the 
protein–this possibility will be examined in the next chapter.
G6PD was known to be involved in PPP and protecting organisms from oxidative stress that 
can be lethal if insufficient NADPH were produced.1 The NADPH produced is not only 
crucial for the survival of organisms, but also has considerable commercially importance.2 
The G6PD enzyme is one of the industrially important enzymes that are widely applied 
clinically. It has been used to determine glucose and creatin kinase levels.3, 4 However, the 
application that interest the researchers is for NADPH regeneration for in vitro assays, 
particularly with cytochrome P450s.
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Over the past decade, G6PD enzymes from various sources have been purified and 
characterized. Properties such as expression, kinetics parameters, substrate and cofactor 
specificity, temperature, and optimum pH were commonly determined.5, 6 Of these 
properties, thermal stability was one of the major interests for industrial chemists. 
Biotechnologists typically look for enzymes that function over a broad range of temperatures 
(particularly at higher temperatures). Therefore, enzyme engineering often involves 
searching for improvements in thermostability.
It was noted in Chapter 1 that a considerable number of mutations in human G6PD have 
been identified and partially characterized. The mutations appear to have been selected for 
on the basis of their ability to confer some resistance to Malaria. This resistance can be 
achieved via a number of mechanisms. The human mutations are almost all point mutations 
that can affect protein stability in either a beneficial or detrimental way. To date, over 150 
human G6PD variants have been identified at the DNA level.7 Among the mutations found, 
most were found to cluster at the dimer interface or close to structural NADP+ binding site-
crucial sites for stability of G6PD protein.1 The mutations at this site would probably alter 
the stability and likely the conformational changes of the G6PD protein. In this study, 
several mutations were found to reside close to the structural NADP+ site. This, prompted us 
to investigate the effects of some of such mutations in some of the variants of the E. coli 
protein that were identified in Chapter 4. 
As G6PD is widely distributed in animal tissues, plants, and microorganism, this cytosolic 
enzyme has been purified and characterized extensively. Numerous reports regarding the 
stability, kinetics and the effects of the mutations on the phenotype of G6PD were available 
at the time this study commenced. Such studies increase our understanding of G6PD. 
However, these mutations have usually been generated using site directed mutagenesis with 
the aim of testing a specific hypothesis. They generally give rise to variants that have 
reduced or minimal activity. Despites this drawback, these mutations have frequently been a 
powerful tool in structure/functions studies. Directed evolution provides variants that have 
been selected (or screened) on the basis of some property. These variants offer a new and 
different approach to structure/function studies. They identify mutations that give rise to 
enhanced activity – they have the potential to tell an investigator how to engineer a protein 
for this activity. 
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In this study, four mutants isolated in this project were selected for characterization and 
compared with the native G6PD protein. We analyzed the stability of the G6PD proteins in 
physical and chemical denaturants, as well as the kinetic properties. We also used a protein 
modeling software, Phyre2, to predict and model E. coli G6PD tertiary structure in order to 
investigate the location of the mutations. 
5.3 Materials and methods
5.3.1 Materials
The recombinant constructs of G6PD were created by random mutagenesis as described 
previously in Chapter 4. The recombinants were expressed and purified as explained in 
Chapter 3 (section 3.3.3.2). All experiments described in this chapter used dialysed purified 
protein. Assays for G6PD were performed by measuring the formation of the orange color of 
a formazan at 460 nm. Unless stated otherwise stated, assays were carried out at 25 °C. The 
final concentrations of assay components were, 0.02 mM for PMS, 0.5 mM for WST-8, 0.01 
mM for NADP+, 0.05 mM for G6P, 10 mM for MgCl2 and 0.1 M for Tris-HCI at pH 7.65. 
Assays were performed in 96-well plates unless mentioned.
5.3.2 Methods
5.3.2.1 Thermal inactivation assay
For this assay, the enzyme activities were measured twice, once prior heat treatment and 
once after heat treatment. Prior to heat treatment (control), 10 μL samples of the protein at 4 
μM were transferred into 96-well plates and the enzyme activity was measured at 25 °C. 
Heat treatment consisted of 20 minutes incubation at various temperatures ranging from 30 
°C to 80 °C followed by 3 minutes on ice before measuring the residual activity. The 
incubations utilized a thermocycler. Samples (each 30 μL) of each protein were placed in the 
wells of PCR plates. Sample was centrifuged for 30 seconds prior for incubation. After 
incubation, 10 μL of the heat-treated samples were transferred to 96-well flat bottom plates 
to measure the residual activity. The residual enzyme activity was determined in triplicate 
and expressed as a percentage of the enzyme activity prior to heat treatment. The final 
enzyme concentration used in the assays was 0.2 μM and the final volume of the reaction 
mix was in 200 μL.
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5.3.2.2 Time dependence of residual G6PD activity after heat treatment at 60 °C  
The experiments described in the previous paragraph give an indication of protein stability 
tested at variety of temperature for a fixed time. They give very little indication of the ability 
of mutants to withstand modest heat treatment for prolonged periods of time. It was known 
the half-life of the native protein was 58 °C under these conditions and that the native protein 
had close to zero activity after treatment at 60 °C for 20 minutes. An attempt was made to 
determine the enzyme half-life at a temperature known to decimate the activity of native 
protein within 20 minutes. 
Purified G6PD enzymes (30 μL) were freshly diluted to 4 μM and heated at 60 °C for 2 
hours using a thermocycler. During this process, 10 μL aliquots were taken to measure the 
residual activity at every 30 minutes as described in the previous section. The residual 
activities were measured in triplicates taken at 25 °C.
5.3.2.3 Urea denaturation monitored by activity assay or intrinsic fluorescence
In order to probe the stability of the enzymes with respect to chemical denaturants, urea 
denaturation was carried out as follows. Enzymes were incubated for 6 hours at room 
temperature, with urea concentration ranging from 0 to 6 M in 50 mM sodium phosphate 
buffer at pH 7.65. The concentration of enzyme in the final mixture was 4 μM. To ensure 
uniform mixing, the mixtures were thoroughly mixed by inverting them several times in 
Eppendorf tubes prior incubation. The residual activity was then measured as described in 
the previous two sections: 10 μL of sample was added to 190 10 μL of reaction mix and the 
course of the reaction monitored at 460 nm. 
For the intrinsic fluorescence measurements, 180 uL samples were measured in black 
fluorescence plates using spectrophotometer. The fluorescence spectra were recorded after 
an excitation at 280 nm with the emission at 300-380 nm recorded using a 5 nm slit. A blank 
for each urea concentration served as control.
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5.3.2.4 Determination of Optimum pH
The optimum pH value was determined by measuring the G6PD activity in solutions with 
pH from 5.5 to 9.0.  The buffer contained 50 mM Tris, 25 mM MES and 25 mM acetic acid. 
The pH was adjusted using HCI and NaOH. The final concentration of purified enzyme was 
at 0.1 μM.
5.3.2.5 Steady-state kinetic studies
The kinetic parameters were measured using a method described by Cook and Cleveland 8, 9, 
for sequential bi-substrates enzymes. There was a shortage of WST-8 dye and so for these 
experiments, the extent of reactions were monitored by observing spectral changes of 
NADP+ at 340 nm (ε340 = 6.22 mM-1 cm-1) as described in Chapter 3 (section 3.3.3.5).
All substrates and diluted samples were freshly prepared before the initial rates were 
measured. The steady-state kinetics for G6P were performed by fixing the concentration of 
NADP+ (0.1, 0.25, 0.5 and 1 mM), while varying the concentration of G6P (0.1-4 mM). 
Likewise, the steady-state kinetics for NADP+ were performed by holding the G6P at 0.1, 
0.25, 0.5 and 1 mM, with different concentrations of NADP+ ranging from 0.03-1.5 mM. 
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5.4 Results
5.4.1 Selection of thermostable variants for characterization
Four thermostable variants, G6PD2-12 (second round), G6PD3-44 (third round), G6PD7, 11F 
(fourth round), and G6PD2, 2G (fourth round) were selected for characterization based on the 
crude lysate thermostability assays. The selected variants had the highest thermostability 
observed in the directed evolution performed. No variant was selected from the first round of 
evolution as only 20% of the thermostability observed. As can be seen in Figure 5.1 below, 
all variants were more stable and active compared with the native enzyme. There was a rapid 
increase in stability in the second round of evolution while the changes between the third and 
fourth round were relatively modest. By the fourth round the stability as measured was 
above 90% – further improvements would have required a change in screening conditions. 
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Figure 5.1 Thermostability of G6PD variants in E. coli crude lysate. The thermostability is 
represented by the right y-axis that was calculated by dividing the activity at 60 °C (20 minutes 
incubation in thermocycler) over the initial activity at 25 °C. 
5.4.2 Thermostability of E. coli G6PD WT and variants at varying temperatures
The stability of the E. coli G6PDWT and its variants were analyzed by irreversible thermal 
inactivation. The purified enzymes were incubated for 20 minutes at temperatures from 30 
°C to 80 °C before the enzyme activity was assayed in accordance to section 5.3.2.2. Figure 
5.2 shows that all mutant enzymes were more stable than the native enzyme. The curves in 
Figure 5.2 were fitted with points at a given temperature that were the average of 3 
observations. To within experimental error, 
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the activities of G6PDWT and all variants were not affected when incubated at temperatures 
between 30 °C and 50 °C. After incubating at 60 °C, three variants were still active with 
more than 50% of their original activity, whereas the G6PDWT approached complete thermal 
inactivation – retained approximately only 15% of its original activity. 
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Figure 5.2 Thermostability of G6PDWT and evolved variants. Stability activity plots were calculated 
based on the residual activity after heat treatment at different temperatures. The graph was fitted 
using a modified Hill equation in Kaleidagraph software. Mean of three replicates with error bars 
indicating the standard deviation. 
The apparent melting temperature (Tm50) was taken as being the temperature at which the 
enzyme retained half its initial activity. The Tm50 of G6PDWT and variants were determined 
using the data in Figure 5.2, above, and displayed below in Table 5.1. For each enzyme, 
three samples were tested and curves fitted and a Tm50 determined. The results again 
displayed that the variants enzymes were more stable than the G6PDWT by about 3-7 °C 
difference in the Tm50 values. The error bars suggested that there is only significant 
differences in Tm50 between the G6PDWT (59 ± 2) and two variants − G6PD7,11F (64 ± 0.5) 
and G6PD2, 2G (66 ± 2). Slight differences in Tm50 between G6PDWT (59 ± 2) and the G6PD2-
12 (62 ± 2) and G6PD3-44 (62 ± 1) evolved variants could not be distinguished since all were 
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within error. The melting temperature for G6PDWT obtained from this study differs slightly 
from a previously reported Tm50 of approximately 55 °C for native human G6PD enzyme.10
As compared to native G6PD, the improvement of only 3°C in the Tm50 for the second 
(G6PD2-12) and the third round (G6PD3-44) of evolution was quite modest. The mutations 
found in the mutant proteins are shown in Table 5.1. The G6PD2-12 variant had only two 
mutations (S253T and T428A) of which only one was observed in G6PD3-44. The loss of the 
T428A change was compensated for by four additional changes observed in G6PD3-44. 
However, of these four changes, only three appear in the 7,11 mutant of the fourth round.  
This would suggest that the R485C mutation had a detrimental effect on stability. This latter 
mutation is also present in the 2,2G variant found in the 4th generation. This variant has, 
within experimental error, retained above 90% of its activity in themostability assay 
suggesting that the two of the three differences (i.e. D254G and T428A) have more than 
compensated for any detrimental effects due to the R485C change. 
Table 5.1 Point mutations identified on G6PD stable variants
Amino acids position
Generation 253 254 356 401 416 428 485 Apparent 
Tm50 (°C)
G6PDWT S D E I H T R 59 ± 2
2nd G6PD2-12 T A 62 ± 2 (3)
3rd G6PD3-44 T V V R C 62 ± 1 (3)
4th G6PD7, 11F T V V R 64 ± 0.5 (5)
4th G6PD2, 2G T G V V R A C 66 ± 2 (7)
Value in parentheses showed the improvements of the apparent melting temperature (Tm50 ).
5.4.3 Time-course study of G6PD WT and variant enzymes activity
As compared to G6PDWT, all variants still retained over 50% of their original activities after 
30 minutes of incubation at 60 °C (Figure 5.3). The G6PDWT retained less than 8% of the 
activity after 30 minutes of incubation. The results again showed that, all variant enzymes 
were more stable than G6PDWT. Both G6PDWT and G6PD2-12 were inactive after 120 minutes 
of incubation. However, G6PD3- 44, G6PD7, 11F and G6PD2, 2G still retained 10%, 52.4% and 
93.9% of their initial activity, respectively. The data in Figure 5.3 did not fit a simple 
exponential decay. This is probably because denaturation involves several steps according to 
the oligomerization – G6PD is known to exist in mixture of oligomers.1, 11
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Figure 5.3 Time-course stability of G6PDWT and recombinant enzymes. The enzymes were 
incubated at 60 °C for the indicated times and the results were presented in residual activity. Mean of 
three replicates with error bars indicating the standard deviation.
The G6PD2, 2G was undoubtedly the most thermostable mutant. Even after 120 minutes of 
incubation, the variant retained over 90% of its initial activity – significantly better than any 
other variant. There was one change in G6PD2, 2G that is not present in any other variant and 
that is the D254G change. The G6PD2, 2G variant demonstrates that simply increasing 
incubation time by a factor of three in directed evolution selection would not provide useful 
selection pressure to further improve G6PD stability. Further evolution should involve 
screening at a higher temperature. 
5.4.3.1 Expression of G6PD WT and variant enzymes
During the purification of the native and variant enzymes, it was noted that compared to the 
native enzyme, the G6PD2-12, G6PD3-44, and G6PD7,11F variants appeared to have similar 
expression and solubility (data not shown) while that of the 4th generation variant, G6PD2, 2G 
appeared to have distinctly lower levels of expression. It seemed, that mutations responsible 
for enhanced thermal stability could also affect the expression of the G6PD2, 2G variant. The 
electrophoresis gel in Figure 5.4 showed the expression level of the variant in comparison 
with G6PDWT. From the figure, the variant had a leaky expression; it was still being 
expressed even without IPTG induction. However, it was poorly expressed even after grown 
overnight at 25 °C.  
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1: (-IPTG) at 37°C
2: (+IPTG) at 37°C
3: (+IPTG) at 25°C
4: (+IPTG) at start
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Figure 5.4 Protein expression analysis of G6PDWT and a variant, G6PD2,2G by SDS-PAGE. The 
electrophoresis gel displayed the crude fractions of the tested culture after certain expression time. 
Each of the wells were loaded with 5 μL of sample. The red box highlighted the poor expression of 
the G6PD2, 2G. The gels contained a 4% (w/v) stacking region and a 15% (w/v) separating region, 12 
both prepared from a 37.5:1 ratio of acrylamide to bisacrylamide. Lane 1 (no IPTG grow at 37 °C); 2 
(induced with 0.5 mM IPTG and expressed at 37 °C); 3 (induced with 0.05 mM IPTG and expressed 
at 25 °C); 4 (induced with 0.5 mM IPTG at start and expressed at 37 °C).
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5.4.4 Changes in response to chemical denaturation − Urea
Here we investigate the influence of increasing concentrations of urea on the residual 
enzyme activities of variant enzymes (Figure 5.5 A). 
In urea stability assay, all variants were found stable in the presence of more than 3 M of 
urea after 6 hours of incubation, whereas, G6PDWT retained less than 10% of activity (Figure 
5.5 A). When the concentration of urea was increased from 0 M to 3 M, drastic decay in 
enzyme activity was observed for G6PDWT and G6PD2-12. A loss in activity of 90.4% was 
recorded for G6PDWT and 59.2% for G6PD2-12. In contrast, G6PD3-44, G6PD7, 11F and G6PD2, 
2G variants showed almost no loss of activity. Specifically, a loss in activity of only 5% was 
recorded for G6PD3-44, 12.5% for G6PD7, 11F and 6.3% for G6PD2, 2G. These three variants 
were very stable in urea. Even at 4 M urea, G6PD3-44, G6PD7, 11F and G6PD2, 2G still retained 
32.3%, 64.5% and 76.3% of their original activity, respectively. At least 3-5 M of urea were 
required to completely denature the variant enzymes. Overall, the T50 (urea concentration at 
which half the protein denatured) for G6PDWT, G6PD2-12, G6PD3-44, G6PD7, 11F   and G6PD2, 
2G was 1.99 M, 2.71 M, 3.81 M, 4.10 M and 4.20 M, respectively. The standard error for the 
T50 reported here was ± 0.3. In summary, the chemical stability (resistance to urea) increased 
with successive generations of directed evolution − all variants were stable with respect to 
urea denaturation with stability increasing by a factor of approximately 2.
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Figure 5.5 Effects of increasing concentrations of urea on residual activity loss and intrinsic 
fluorescence. (A) Urea denaturation of G6PDWT and the variants under study. Results were 
expressed as percentages (%) with respect to the activity of the enzymes in the absence of urea. (B) 
Intrinsic fluorescence emission plot of urea denaturation. The experiment was performed at 0.2 μM of 
enzyme solutions in the presence of varying urea concentration following 6 hr of incubation at 25 °C 
Data presented represent the mean of triplicates data measured. 
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The intrinsic fluorescence spectra were used to monitor changes in local environment of 
tryptophan residues during the unfolding of the enzymes, as exposure of the residue to 
solvent will affect the fluorescence. Human G6PD enzyme has a total of 7 tryptophan 
residues, while the E. coli G6PD has 12 tryptophan residues per monomer. Two of the 
tryptophan residues were located in close proximity to the dimer interface (W349 and 
W225). It was known that the dimer interface is crucial for enzyme stability.1, 13 
In the absence of urea the wavelengths for maximal emission of the G6PDWT, G6PD2-12, 
G6PD3-44, G6PD7, 11F   and G6PD2, 2G enzymes were 338 nm, 335 nm, 340 nm, 338 nm and 
335 nm, respectively (Figure 5.5 B). In the presence of increasing urea concentration, red 
shifts in the emission spectra were observed, indicating the increasing exposure of the 
tryptophan residues to the solvent. Shifts of 12, 15, 5 and 13 nm were observed for G6PDWT, 
G6PD2-12, G6PD3-44, G6PD7, 11F, respectively. This shift suggested that there might be some 
differences in the microenvironment of the tryptophan residues. The unfolding pattern 
G6PDWT displayed a major shift observed at urea concentrations between 1 M to 2 M (from 
333 nm to 340 nm, before became linear from 2 M onwards. This shift coincides with the 
dramatic activity loss in G6PDWT (Figure 5.5 A). Similar unfolding pattern was observed for 
G6PD3-44, for which the major shift occurred at urea concentration of 3 M to 4 M (Figure 5.5 
B). However, G6PD2-12, G6PD7, 11F and G6PD2, 2G showed different displacements of the 
emission spectra. Three phases were recorded for G6PD2-12 and G6PD7, 11F  whereas, four 
phases for G6PD2, 2G. The first phase was recorded at 1-2 M, second phase at 2-3 M, third 
phase at 3-4 M (for G6PD2, 2G) and the fourth phase (3-5 M for both G6PD2-12 and G6PD7, 11F   
and 4-5 M for G6PD2, 2G).
In conclusion, these findings postulate that the microenvironments of tryptophan residues in 
the G6PD variants might be different from those in the native G6PD. 
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5.4.5 Determination of optimum pH 
The optimum pH for the activity of native and variants of G6PD was 8.5 as can be seen in 
Figure 5.6. Similar optimum pH was observed in pig liver G6PD.14 However, the result 
differed with reported optimum pH for G6PD from human placenta (pH 7.8) and lamb 
kidney cortex (pH 7.6 to 7.8).15, 16 The plots of the pH dependence of activity for the variants 
are quite different and different to that of the native. For example, the profile for G6PD2, 2G is 
shifted to lower pH whereas G6PD7, 11F shows much less activity at lower pH. It is tempting 
to speculate that the difference could represent differences in stability, but the possibility are 
more likely due to changes in the pH of ionisable groups like Histidine in response to 
different microenvironments. 
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Figure 5.6 The pH optimum curves for G6PD activity. The activity is expressed relative to the 
maximum activity at pH 8.5. Data points represent the mean of triplicates data measured.
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5.4.6 Kinetics parameters
Kinetic parameters of the G6PDWT and variants were determined and the results given in the 
table below (Table 5.2). The kcat values for the native E. coli G6PD determined in this study 
were similar to those values reported for E. coli G6PD (ranging from 87-174 s-1).17, 18 The 
reported Km values for G6P and NADP+ determined with the E. coli G6PD enzyme were in 
the range of 0.1-0.2 mM and 0.008-0.015, respectively.17, 18 Differences between the 
reported values and those determined in the study could be attributed to the different 
experimental methods and conditions in their determinations as well as the purity of 
substrates used.
Among the variants, G6PD3-44 showed the highest catalytic constant (kcat) value (254 ± 4 s-1). 
The kcat values obtained were as follows:  G6PDWT (146 ± 7 s-1), G6PD2-12 (223 ± 15 s-1), 
G6PD7,11F (139 ± 4 s-1) and G6PD2,2G (170 ± 14 s-1). The data presented in Table 5.2 showed 
that, G6PD2-12 and G6PD3-44 were slightly more active than the G6PDWT, whereas the kcat 
values for G6PD7,11F and G6PD2,2G were within the error G6PDWT. In summary, the 
differences between native and variants are, at most, modest. 
Table 5.2 Enzyme kinetics data of G6PDWT and variants 
G6PDWT G6PD2-12 G6PD3-44 G6PD7,11F G6PD2,2G
kcat (s-1) 146 ± 7 223 ± 15 254 ± 4 139 ± 4 170 ± 14
Km G6P 
(mM)
0.3 ± 2 0. 3 ± 0.06 0.18 ± 0.1 0.3 ± 0.06 0.19 ± 0.2
KmNADP+ 
(mM)
0.05 ± 0.1 0.11 ± 0.1 0.03 ± 0.05 0.069 ± 0.02 0.024 ± 0.01
kcat / Km G6P 
(s-1. M-1) x 103
490 743.3 1411.1 463.3 894.7
kcat/Km NADP+ 
(s-1. M-1) x 103
2920 2027.3 8466.7 2014.5 7083
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5.4.7 Location of the point mutations of G6PD variants under study
Molecular structure provides a great deal of information that is useful to understand how 
molecules function. The information that can be gained from a structure depends upon a 
number of factors that include the resolution of the structure and the ligation state of the 
protein used to determine the structure. High resolution of protein structures can be obtained 
using x-ray crystallography. Unfortunately, there is no E. coli structure available in the 
protein database, so a model was generated (predicted) with the Phyre2 protein modeling 
software19 using structures of the closest homologues that have more than 30% identity. 
Among the structures that were used as the templates were: human G6PD (PDB: 1QKI17, 
41%; 2bhl20, 37%), L. mesenteroides (PDB: 1h9a, 34%)21 and T. cruzi (PDB: 4e9i, 36%)22. 
This model is probably accurate in a gross sense; that is, domains have been correctly 
predicted, but it was not be prudent to assign interactions between residues since these would 
require a very accurate model.
Structures of other G6PDs as well as other dehydrogenases provide some idea of the cofactor 
and substrate-binding site is available. A second NADP+ binding site, thought to be 
important for subunit interactions is also known.11, 23 Among the four characterized stable 
mutants, a total of seven point mutations were observed – S253T, D254G, E356V, I401V, 
H416R, T428A and R485C. Most of these mutations were not conserved; only D254G and 
T428A are weakly conserved in the human G6PD structure (Figure 5.7). Two mutations, 
I401V and R485C, occur near the dimer interface and the structural NADP+ and the C-end 
terminal site, respectively. Three mutations, S253T, D254G and E356K reside at the back 
loop of the “structural” domains and one mutation; T428A was at the middle boundary 
between the two domains (Figure 5.8). 
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Figure 5.7 Sequence alignments of G6PD proteins. Positions of the mutations in E. coli G6PD 
variants found in this study are configured in squares. Sequences used are Human G6PD (PDB: 
1QKI), L. mesenteroides (PDB: 1E7Y), and T. cruzi (PDB: 4e9ib). 
Asterisk (*) indicates positions, which have a single, fully conserved residue.
Colon (:) indicates conservation between groups of strongly similar properties.
Period (.) indicates conservation between groups of weakly similar properties.
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(B) (C)
Figure 5.8 The location of mutations from predicted model structure by Phyre2 modeling software. 
NADP+ is shown as a stick. S253T (red), D254G (orange), E356K (magenta), I401V (green), H416R 
(yellow), T428A (blue) and R485C (dark blue) are showed as spheres. (A) Dimers of E. coli G6PD 
with structural NADP+ (B) Front views of the mutations for the four characterized mutants – different 
colours indicates different domains (C) back views of the mutations.
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5.5 Discussion
The G6PDWT protein has been successfully evolved and the purified variant proteins have 
been demonstrated to enhance stability. The screening process involved a thermal stress, but 
tests with chemical denaturants show that, as one would expect, that the proteins also have 
enhanced resistance to common chemical denaturant: urea. The increased stability as 
reflected in the Tm50 values could be described as modest, but one would expect that further 
rounds of evolution would produce more significant gains. The methods that could be used 
in future experiments have also been outline in this thesis. This work has identified two 
approaches to the critical aspect of evolving G6PD, that is the methods used to screen for 
enhanced activity. Two such methods have been tested. The agar plate screen enabled large 
libraries to be screened, but the resulting mutants gave smaller increments in stability 
compared with the final screen that utilized a mutant library with a higher mutation rate and 
a quantitative determination of the stability (in the primary screen). The second method 
proved to be the better method in the present study and would be the first choice for future 
studies given a few minor changes could be made.
Characterization of the G6PD2,2G variant gave a number results that could be useful in 
designing future experiments. Although this mutant gave only a modest increase in Tm50, its 
temporal stability at 60°C was impressive; very little activity was lost after 2 hours of 
incubation. Clearly, future screens should involve heat treatment at higher temperatures; 
68°C to 70 °C would be possible candidate temperatures as this would completely inactivate 
the current mutants. 
The expression of the G6PD2,2G variant was reduced compared to that of G6PDWT. This 
observation suggests that enhancing the stability of G6PD may be toxic to the cell. Some 
emphasis should be placed on the word “may”. The results obtained to-date are only 
suggestive, but given the key role played by G6PD in metabolism, it would not be surprising 
if mutant forms of the enzyme had detrimental effects on the cell. In the present work, 
variants are expressed constitutively. It may be useful to try another expression system that 
allows protein turned on after the cells have grown.  
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5.5.1 Effects of mutations on stability
Mutations in the human G6PD protein cause several phenotypes in the deficiency, which are 
classified according to the in vivo enzyme activity. The mutations found so far have been 
found to effect the catalytic activity, expression and stability of the enzyme.24, 25 In human 
G6PD, the mutations occur close to the structural NADP+ site (487 to 515 amino acids) or at 
the surface of the dimer interface (380 to 425 amino acids) strongly effect the stability of the 
enzyme as it influences the functional structure of the protein.26 The results obtained in this 
study gave mutations that increased stability and had little effect on activity. Based on the 
multiple homologous sequences alignment performed, 1QKI from human deletion variant17, 
1E7Y from L. mesenteroides27, and 4e9i from T. cruzi22 – only D254G and T428A are 
weakly conserved, and the rest are not (Figure 5.7). The seven point mutations found: 
S253T, D254G, E356V, I401V, H416R, T428A and R485C, reside mostly at the helices in 
the large domain close to the structural NADP+ (Figure 5.8). Among the mutations, S253T, 
I401V, H416R, T428A and R485C are highly conserved through the multiple generations of 
evolution performed in this study. These mutations stabilize the protein. A possible 
explanation could be that the changes to the smaller side chain amino acids may provide 
flexibility that ideally suited for better structural packing. In addition, the solvent exposed 
residues like S253T and E356V that reside at the helices reduced the flexibility of the loops 
and also causes efficient packing. Better packing and reduced flexibility of the loops at 
solvent exposed residues is a characteristic of thermophilic enzymes.28-30
Mutations that occur at the dimer interface normally destabilized a dimeric proteins.1, 10, 13 
Among the mutations in this study, the I401V resides at the surface of dimer-interface 
(Figure 5.7, yellow sphere) and in contrast, stabilized the protein. Although the stabilizing 
effect may be exerted due to smaller side chain residues changed, the changes may have 
cause some conformational changes in the dimer surface interaction. At this stage, we could 
not confirm this because the I401V mutation is present with other mutations in the variants – 
a variant with only I401V mutation on the gene should be constructed to validate the effect. 
The mechanism for thermal denaturation of protein is widely known; heat increases the 
kinetic energy causing increasing vibrational motions that results in the formations of molten 
globules and denaturation.31 In contrast, the mechanism for urea denaturation of protein is 
still subject to debate.32 Several possible mechanisms have been reported − indirect 
mechanism where the urea infiltrates the water hydrogen bonds and altered the solvent 
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environments or by binding and stabilizing to the protein in its denatured state.33-35 As for 
G6PD, Scopes et al.13 found that the presence of urea caused disruption of dimer-interface in 
human G6PD as confirmed by circular dichroism, whereas the addition of coenzyme NADP+ 
to the protein stabilised the dimer. They also found that, the mutation (D421K at the dimer 
interface) with increased thermostability reduced the stabilizing effect of the NADP+ against 
urea denaturation. The NADP+ has been known to exert stabilizing effect on the G6PD 
dimer. However, our results to some extent differed – even in absence of NADP+, all 
variants were highly stable against urea denaturation compared with G6PDWT. These results 
agreed with previous studies that had shown that increased thermal stability likely 
corresponds to increased chemical stability.37 This is also consistent with the finding in 
which thermophilic enzymes are often highly tolerant to chemical denaturants and organic 
solvents.38, 39
5.6  Conclusion
The E. coli G6PD variants characterized in this chapter showed excellent stability in both 
thermal inactivation and urea denaturation compared to the G6PDWT. Several promising 
mutations − S253T, E356V, I401V, H416R, T428A, and R485C were identified to affect 
both stability and catalytic properties of E. coli G6PD. These mutations were conserved in 
variants that conferred the stability in both thermal inactivation and urea denaturation. In 
view that most of the mutations mentioned were located at the loops of the “structural” 
NADP+ binding domain and close to the dimer interface, the stability conferred might be due 
to better compactness and organized tertiary structure. The mutations also contributed to 
higher catalytic constant as measured in the steady-state kinetics. In this study, the effects of 
the mutations on structural level could not be determined due to the short time course of the 
candidature. Thus, it would be great interest to investigate the effects on structure via 
techniques like circular dichroism or light scattering. This work is also not yet completed, 
but could serve as a platform for better evolution, be it rational or directed evolution with 
these pre-existing level of stability. 
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6.1 Preamble 
 
Numerous studies reported that most soluble proteins associate to form what was called the 
quaternary or oligomeric structure of the protein.1, 2, 3 This, in turn, led to a great deal of 
speculation as to why this is so −“why do proteins form oligomers?”. Much, but not all, of 
this speculation, has revolved around the idea that quaternary structure increases protein 
stability. The speculation concerns regulation. Indeed, it is known that most co-operative 
regulation involves a change in the oligomeric structure of the protein. Now, G6PD is known 
to exist in multiple oligomeric forms, and it is also known that the activity of this enzyme is 
required to be switched on and off depending upon the needs of the organism. However, a 
detailed understanding of the relationship between activity and oligomeric structure is not 
known and how the oligomeric structure affects the stability of this important enzyme is 
even less well understood. We have evolved variants of G6PD that are active and that have 
enhanced stabilities. We now want to gain some understanding of how the oligomeric 
structure affects stability and eventually the activity of an enzyme. As part of this study, we 
also examine the oligomerization of the E. coli G6PD as a function of protein concentration. 
 
6.2 Introduction 
 
 
There are numerous reports of thedifferent oligomeric forms of G6PD.4, 5A study on cyano-
bacterial G6PD by Sundaramet al.4noted that glucose, stimulated the formationof different 
oligomeric forms: hexameric, tetrameric and dimeric forms were observed to arise from the 
same monomer. There are various factors that can contribute to changes in the oligomeric 
structure of G6PDs, such as, pH, salt and metal concentration, intracellular disulfide/thiol 
bonds and other factors that are important for the regulation of the enzyme in metabolism.6, 7 
However, little is known about the oligomerization of the E. coli G6PD protein. 
 
The human G6PD protein and most other naturally occurring variants have two NADP+ 
binding sites−the catalytic coenzyme binding site and a structural binding site, well 
separated from the active site.8Thecrystal structure of a humanvariant revealed that the 
structural NADP+was bound between the β sheets in the dimer interface near to the C-ends 
terminal. Mutations located near to the structuralNADP+binding site are known to affect the 
stability of human G6PD.8 By way of contrast, our results reveal that the point mutations 
located near to the structural NADP+ site conferred stability to the variants under study−refer 
to Chapter 5. In this chapter, a description is given of experiments to examine the oligomeric 
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structure of the variants that were evolved to have enhanced stability. Size exclusion 
chromatography and native gel electrophoresis were used to determine the oligomeric forms 
of the G6PD variants. The results also may help to understand the oligomerization, stability, 
and function ofG6PD proteins.  
 
6.3 Materials and Methods 
6.3.1 Gel electrophoresis with Glutaraldehyde crosslinked subunits 
 
The methods were described by Fadouloglou et al.9and involved cross-linking subunits and 
running the linked subunits on a denaturing gel as described in Chapter 2.  Crosslinking was 
achieved using formaldehyde as the linking agent. In these experiments, 10 μL samples of 10 
μM (0.6 mg/mL) protein were aliquoted into Eppendorf tubes. Then, 4x-diluted 
glutaraldehyde were added to the samples to a final concentration of 0.5-3% and incubated at 
room temperature for 30 minutes to allow the crosslinks to form.  
 
6.3.2 Size exclusion chromatography 
 
Size exclusion chromatography was performed using a Superdex 200 10/300 GL column 
(GE Healthcare). The column was stored in 20% ethanol and kept at 4 °C. Prior to use, the 
column was washed with 2 column volumes (CVs) of Milli-Q water and equilibrated with 2 
CV of buffer containing 50 mM sodium phosphate at pH 7.4 and 300 mM NaCl. The void 
volume (Vo) of the column was determined with 2 mg/mL of Blue Dextran 2000. The 
column was calibrated with 0.1 mL standard solutions that contained 3 mg/mL 
Thyroglobulin (a dimer of approximate molecular weight 660kDa); 0.7 mg/mL Ferritin 
(consist of 24 subunits with and approximate molecular weight of 474 kDa); 4 mg/mL 
Aldolase (a tetrameric enzyme of approximate molecular weight 160kDa); 3 mg/mL 
Conalbumin (a dimer of approximate molecular weight 76 kDa) and 4 mg/mL Ovalbumin (a 
monomer of approximate molecular weight 45 kDa). Experiments were run at 0.5 mL/min 
with sample volumes of 0.1 mL. The molecular mass of the protein was calculated based on 
the calibration curve of log molecular weightversus the distribution coefficient (Kav) where 
Kav = (Ve-Vo)/(Vc-Vo) and where Ve = elution volume, Vo = column, void volume and Vc = 
geometric column volume. The standard curve is shown below in Figure 6.1.  
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The equation for log MW (y-axis) against Kav (x-axis) was (y=-5.3852x+25.409). All the 
proteins used were purified as described in Chapter 3 (section 3.3.3.2) and concentrated 
using Amicon concentrator to 20-50 mg/mL. 
 
Table 6.1 Elution data for standard calibration curve using size exclusion chromatography 
 
Standard MW (kDa) Ve Ve -Vo Kav 
Thyroglobulin 669 9.72 1.79 0.111 
Ferritin 440 11.39 3.46 0.215 
Aldolase 158 14.22 6.29 0.391 
Conalbumin 75 15.22 7.29 0.454 
Ovalbumin 43 16.31 8.38 0.521 
 
The Superdex 200 HR 10/30 column had a Vc of 24 mL and a Vo of 7.93 mL measured using blue 
dextran. At 0.5 mL/min speed, the sample was run for approximately 50 minutes to be completely 
eluted. 
 
 
Figure 6.1Standard calibration curve used to determine the molecular weight of E. coli G6PD subunit 
by size exclusion chromatography. The logarithm of the molecular weight (MW) of the standard 
proteins was plotted against their elution parameter Kav. The coloured dots represent the expected 
Kav of the oligomers calculated from the linear equation of graph elution volume against log MW (y=-
5.3852x+25.409). 
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Figure 6.2Estimated ranges of elution volumes for oligomers of G6PD. The values were calculated 
from the linear equation of graph elution volume against log MW (y=-5.3852x+25.409). 
 
 
6.4 Results 
6.4.1 Selection of recombinants for polymerization study 
 
 
The variants characterized in Chapter 5 (summarized in Table 6.2) were used to investigate 
the correlation between the improved protein stability and oligomerization of G6PD. 
 
Table 6.2A complete list of variants and the stability 
Gen AA 253 254 356 401 416 428 485 Tm50 
(°C) 
kcat (s-1) 
 G6PDWT S D E I H T R 59 ± 2 146 ± 7 
2nd G6PD2-12 T     A  62 ± 2 223 ± 15 
3rd G6PD3-44 T  V V R  C 62 ± 1 254 ± 4 
4th G6PD7, 11F T  V V R   64 ± 0.2 139 ± 4 
4th G6PD2, 2G T G V V R A C 66 ± 2 170 ± 14 
 
The melting temperature (Tm50) is the temperature at which half of the protein unfolded still retained 
after incubation at a range of temperatures. For this assay, the purified proteins were incubated for 
20 minutes at the temperature ranged from 30 °C to 80 °C. 
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6.4.2 Multiple forms of E. coli G6PD – gel electrophoresis  
 
 
In this study, the purified native E. coli G6PD was subjected for glutaraldehyde crosslinking 
to obtain information on the oligomerization state of the protein. The simplicity of the 
procedure and the availability of the glutaraldehyde in the laboratory led to this approach 
being tested for oligomerization study.10 
 
 
 
Figure 6.3 Glutaraldehyde crosslinking of native E. coli G6PD protein for identification of quaternary 
protein structure. The protein at 0.6 mg/mL was used, and 5 μL was loaded onto 10% SDS-PAGE 
gel.Blue arrow indicates the bands appeared. Lane 1–no addition of glutaraldehyde, lane 2–0.5% 
glutaraldehyde, lane 3–1% glutaraldehyde, lane 4–2% glutaraldehyde, lane 5–3% glutaraldehyde. 
M–standard marker. 
 
 
Figure 6.3 shows the gel obtained with the crosslinked E. coli G6PD protein. As seen in the 
gel, multiple bands corresponding to different molecular mass were observed with 
glutaraldehyde.Without glutaraldehyde treatment, there was a monomeric band at 
approximately 58 kDa. However, the higher oligomeric form started to appear once induced 
by glutaraldehyde with a molecular mass of approximately close to 200 kDa (Lane 2-5). This 
molecular mass is corresponding to a tetramer. However, at 2% and 3% (Lane 4 and 5), two 
more faint bands were observed trapped at the interface of the stacking gel and running gel. 
These appear to be oligomers that have molecular masses of greater than 200 kDa that may 
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be due to higher order structures. There did not appear to be any evidence for a dimer. More 
likely, under the conditions for glutaraldehyde reaction tested, G6PD predominated as a 
tetramer. Nevertheless, the evidence proved that the native E. coli G6PD protein exists in 
multimeric forms. Further study was performed using size exclusion chromatography. 
 
 
6.4.3 Molecular mass of E. coli G6PD – size exclusion chromatography  
 
 
We evaluated the oligomeric forms of E. coli G6PDWT and the stable variants using size 
exclusion chromatography. Herein, the molecular weight of the protein at 1 mg/mL (100 μL 
sample volume) was calculated using the calibration plot given in Figure 6.1. The expected 
elution volume for different oligomers of G6PD was also estimated using the plot and 
illustrated in Figure 6.2, to give views of the expected range of elution volume for the 
unknown molecular mass of the protein.  
 
An inspection of the elution profile for G6PDWTis given in Figure 6.4. From this figure, it 
can be seen that there two major peaks with elution volumes at 12.42 mL and 14.22 mL that 
were thought to correspond, to a tetramer (255 kDa, 4.4x of monomeric mass) and a dimer 
(120 kDa, 2.1x of monomeric mass). The elution profiles showed a distinct separation of the 
two peaks; that is they are well resolved.  A small peak was also observed at roughly 20 mL 
elution volume corresponds to the elution of salt. There is also a shoulder on the peak for the 
tetramer that probably corresponds to a higher molecular weight species.  
 
The results agreed with observations made with the human enzyme that it was a mixture of 
tetramer and dimer. There has been some work done with the E. coli enzyme that led to the 
conclusion that in addition to a dimeric and tetrameric species, it could also form higher 
molecular weight oligomers.  However, the molecular weight of the large oligomers is 
difficult to determine, as the peak corresponding to this species is not resolved from that of 
the tetramer.  
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Figure 6.4 Size exclusion chromatography elution profiles for polymerization of E. coli G6PDWT 
 
 
It should be noted that on the time scale for running the column, the inter-conversion 
between the dimeric and tetrameric forms is slow. If there were a rapid inter-conversion 
between the different oligomeric forms, then a peak corresponding to the average molecular 
weight would be observed in the elution profile. The protein concentration that gave the 
elution profile in the figure shown above (Figure 6.4) was considered appropriate for testing 
the variant forms of G6PD–it was expected that the more stable forms of the protein would 
show a decrease in the dimer population and an increase in the amount of tetramer.  
 
6.4.3.1 The stable variants show higher oligomers 
Figure 6.5 shows the elution profiles for the evolved variants given in Table 6.2. As in the 
case of the native protein, well-resolved peaks were observed in the elution profiles 
consistent with a slow inter-conversion of the different oligomeric forms. All these profiles 
obtained with the variants differ a great deal from one another and that of the native protein. 
In Figure 6.4, the peak corresponding to the dimer form of G6PDWTwas well resolved from 
the next peak that was assigned to a tetramer. However, the peaks in the variant profiles are 
not well resolved from one another, and this could affect the position of the peak maximum. 
Given the possibility of errors in the determination of the peak maxima and the fact that 
expected positions are close to one another, it is not clear if peaks around 12.4 mL 
correspond to a tetramer or a pentamer.  
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Tetramers are commonly observed in many other forms of G6PD, and it is likely that 
prominent peaks in Figure 6.5b (G6PD3-44), and Figure 6.5 d (G6PD2,2G), as well as the 
shoulder peak feature in Figure 6.5 c (G6PD7,11F), correspond to tetramer. Similarly, 
although a hexamer has been assigned to the prominent peak in Figure 6.5 a, this feature may 
be due to some other species. In Figure 6.5 a, b and c there are prominent features assigned 
to higher molecular weight oligomers; no attempt has been made to assign an oligomeric 
structure. 
 
There was no clear trend in the change of oligomeric structure as directed evolution 
proceeded. In going from the native to the second then third and fourth generations, there is 
no systematic change. Features in the second-generation mutant appear to be quite different 
to those evident in the third and fourth generation mutants. The native protein exhibits a 
prominent peak that corresponds to a dimer; this feature is greatly diminished in the G6PD2-
12 variant and not evident in any of the other variants. Like the profile for G6PDWT, the 
profiles for the first three variants (G6PD2-12 G6PD3-44 and G6PD7,11F) all show indications 
of high molecular weight species that are not evident on the profile for G6PD2,2G. In 
G6PD7,11F, the high molecular weight species appears to be the most abundant. The profile 
for G6PD2,2G suggests that the protein consists of a single species – it was thought to be the 
most suitable for crystallization trials. A summary of the observations of the elution profile 
is given below in Table 6.3. Although there was no systematic change in the oligomeric 
structure as evolution proceeded, it did appear that the evolution (with a selection for 
increased stability) resulted in a shift in the equilibrium between the oligomeric forms–the 
shift being towards the higher molecular weight forms.  
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Figure 6.5 Size exclusion chromatography profiles of G6PD variants by FPLC. The Superdex 200 
HR 10/30 column was equilibrated with 0.05 M Sodium phosphate pH 6.5 and had a Vo of 7.93 mL 
measured using blue dextran. One hundred microliter samples of G6PD protein at 1 mg was loaded 
into and run at 0.5 mL/min. The absorbance of the peak is shown as a relative value rather than the 
absolute value. The monomeric mass of E. coli G6PD native in this study is approximately 58 kDa. 
The asterisk (*) indicates a shoulder peak. 
 
 
 
 
 
 
 
 
 
(a) 
 
(b) 
 
(c) 
 
(d) 
 
Figure 6.5 Size exclusion chromatography profiles of G6PDWT and G6PD variants by FPLC. The 
Superdex 200 HR 10/30 column was equilibrated with 0.05 M Sodium hosphate pH 6.5 and had a Vo 
of 7.93 ml measured using blu  dextran. One hundred microliter samples of G6PD protein at 1 mg 
was loaded into and ru  at 0.5 ml/min. The absorbance of the peak is shown as a relative value rat er 
than the absolute value. The monomeric mass of E. coli G6PD native in this study is approximately 58 
kDa. The (*) indicates a shoulder peak. 
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Table 6.3Molecular forms of the stable variants 
Gen Variants Tm50 
(°C) 
kcat (s-1) Molecular form eluted at 1 mg/mL 
 G6PDWT 59 ± 2 146 ± 7 Tetramer and Dimer 
2nd G6PD2-12 62 ± 2 223 ± 15 Very big form (10.5x monomeric 
mass)* and Hexamer 
3rd G6PD3-44 62 ± 1 254 ± 4 Tetramer and Hexamer* 
4th G6PD7, 11F 64 ± 0.2 139 ± 4 Very big form (11x monomeric mass) 
and Tetramer/Pentamer* 
4th G6PD2, 2G 66 ± 2 170 ± 14 Tetramer/Pentamer 
 
The melting temperature (Tm50) is the temperature at which half of the protein unfolded still retained 
after incubation at a range of temperatures. For this assay, the purified proteins were incubated for 
20 minutes at the temperature ranged from 30 °C to 80 °C. The symbol (*) indicates the shoulder 
peaks. The Tm was measured at 2 μM (0.115 mg/mL), and the kinetics was at 8 nm (0.46μg/mL). 
 
 
6.4.4 Multimers of E. coli G6PDWT vs. G6PDvariants is concentration dependent 
 
In the previous section, it was assumed that the various oligomeric forms of G6PD were in 
equilibrium with one another and that the inter-conversion between the various forms was 
slow on the time scale of size exclusion chromatography. If this were true, then it was 
expected that increasing the concentration of the protein would result in a shift in the 
equilibrium towards the higher molecular weight species. To test this idea, the concentration 
of G6PDWT was increased from 1 mg/mL to 2mg/mL and 5 mg/mL. Solutions of the three 
G6PDWT solutions were run on the size exclusion column and the resulting elution profiles 
were normalized (scaled so that they appear to have same maximum absorption) and 
superimposed as depicted below in Figure 6.6.  
 
It should be clear from Figure 6.6 that simply doubling the concentration of G6PDWT results 
in a drop in the signal for the dimeric species. The position of the second and major peak 
(that for a tetramer/pentamer) appears to shift in the three profiles, but this is probably at the 
level of error involved in the experiment.  All three profiles show a shoulder on the high 
molecular weight side of the major peak. The size of this peak increases as the protein 
concentration increases. The decrease in the size of the dimer peak and an increase in the 
size of the shoulder are consistent with a shift in the equilibrium toward high molecular 
weight species; the nature of the high molecular weight species is not well determined in this 
experiment, but it appears to be larger than a tetramer.  
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The above experiments were repeated for the G6PD3-44 and G6PD2, 2G variants.   The protein 
concentrations tested for these variants were1 mg/mL and 2 mg/mL and the resulting profiles 
shown in Figures 6.7 and 6.8. No change in oligomeric structure was observed for either 
G6PD3-44 or G6PD2, 2G. The G6PD3-44 appeared to remain a mix of tetrameric and possibly a 
hexameric species, while theG6PD2, 2G variant remained a tetramer.   
 
 
Figure 6.6 Oligomerization of E. coli G6PDWT analyzed by size-exclusion chromatography at different 
concentrations of protein 
At 1 mg/mL − dimer (14.22 mL), tetramer (12.42 mL) 
At 2 mg/mL – tetramer (12.49 mL) 
At 5 mg/ml – dimer (14.06 mL), pentamer (12.03 mL) 
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Figure 6.7 Oligomerization of G6PD3-44 variant analyzed by size-exclusion chromatography 
At 1 mg/mL – tetramer (12.6 mL), hexamer (11.67 mL) 
At 2 mg/mL − tetramer  (12.88 mL), hexamer (11.77 mL) 
 
 
 
 
Figure 6.8Oligomerization of G6PD2, 2G variant analyzed by size-exclusion chromatography 
At 2 mg/mL – tetramer/pentamer (11.97 mL) 
At 1 mg/mL − tetramer/pentamer (12.36 mL) 
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6.5 Discussion 
 
The size exclusion experiments demonstrate that in its resting state (with a bound NADP+ in 
the non-catalytic binding site) the E. coli G6PDWT exists in a mixture of oligomers. A 
dimeric and tetrameric species are clearly evident with a high molecular weight species 
suggested by a shoulder on the peak corresponding to the tetrameric species. However, the 
peak for this high molecular weight species grows in prominence in the profiles for G6PD2-12 
and G6PD7, 11F. The peak corresponding to this high molecular weight species may be the 
sum of the contributions of some species that are not resolved by the size exclusion column. 
In summary, the E. coli G6PDWT exists as a mixture of at least three species that are in 
equilibrium with one another and that are inter-converted on a relatively slow time scale.  
 
The G6PD2-12 has similar catalytic properties as G6PDWT but differs in sequence at two 
positions. One of these changes (S253T) appeared in the first round of evolution and 
appeared in all variants by round 4. The second change (T428A) is not present in the G6PD3-
44 variant, yet both G6PD2-12 and G6PD3-44 show little evidence of existing as a dimer. 
Apparently, the S253T change destabilizes the dimer species.  
 
The variants G6PD3-44 and G6PD7,11F differ at only one location, R485C, yet their oligomeric 
structures are quite different. The high molecular weight species that is prominent in the 
G6PD7,11F variant is a minor species in the G6PD3-44 variant. Clearly, the R485C change 
results in a destabilization of the high molecular weight species – or, stated differently, this 
change stabilizes the tetrameric species. The stabilization of the tetrameric species is even 
more evident in the G6PD2,2Gvariant that differs from the G6PD3-44variant by two changes: 
(D254G) and (T428A). The second of these changes occurred in the G6PD2-12 that showed 
very little dimer structure and a great deal of a high molecular weight species. It would 
appear that the T428A change destabilizes the dimer structures, but does not prohibit the 
formation of high molecular weight species. The G6PD2,2G species appears to lack any high 
molecular weight species. This tendency has already been attributed, in part, to the R485C 
change, but the D353G change must greatly contribute to the stabilization of the tetrameric 
species over the high molecular weight species.  
 
The changes E356V, I401V and H416R, have not figured in any of the above discussion. 
The I401V change occurred in the first generation and was most of the variants of the fourth 
generation. The E356V and H416R occurred in one-third generation variant and present in 
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most the fourth generation variants. There are numerous other changes that are not found in 
later generations. This is, in large part, due to the shuffling that occurs when the libraries are 
generated.  To survive, a change must contribute in a positive way to the selection process. 
Clearly, all three changes listed at the start of this paragraph are important, but exactly why 
they are conserved will require further analysis of more variants.   
 
6.6 Conclusion 
 
Directed evolution gave rise to molecules with various oligomeric structures. After only four 
generations, it was not clear which structure would ultimately prove to be the most stable. It 
should be noted that the selection process required that the variant has a significant fraction 
of the G6PDWT activity–mutations that compromised activity were discarded. This is 
probably the reason why mutations near the active site were not observed. The fact that 
changes brought about a change in the oligomeric structure along with an increase in 
stability suggests a strong connection between oligomeric structure and stability.   
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CHAPTER 7
Concluding remarks and future research
132
During the course of this research, the investigator was continually confronted with evidence 
that G6PD was an extremely important enzyme. Like many other metabolic enzymes, it is 
essential for the survival of the organism. However, G6PD does more than just ensure the 
continuity of a pathway. This enzyme sits at the junction of arguably the two most important 
metabolic pathways found in the cell. Variants of the human enzyme are found in a 
significant portion of the population – hence it represents a significant medical problem. The 
implications of these facts are detailed in a number reviews and basic tests. Given the 
importance of G6PD, it is surprising that more is not known about it and that more effort is 
not being put into understanding how the enzyme work. For example, and as noted in the 
introduction, the number G6PD structures is small compared with those that have been 
elucidated for far less important enzymes. The reason for this anomaly is to some extent due 
to the fact that G6PD is an extremely complex enzyme for which the tools needed to probe 
its intricacies are difficult to use.  The work of this thesis provides new approaches to 
understanding a fascinating enzyme. It provides a means to study the kinetics as found in the 
cell – low substrate concentrations with product removed rapidly. It also provides variants 
that have altered properties with activities that are comparable to that of the native enzyme. 
One important property was the oligomeric structure. A variant that was predominantly a 
single oligomeric species was identified, but unfortunately, it did not crystallize. This thesis 
should not be seen as an isolated study, but rather part of a broader study.  It does not answer 
all the questions that one may ask about G6PD, but it does expand our understanding, and it 
also provides tools that others may use in their work. 
The initial objective of this research was to develop an assay for G6PD that would be 
sensitive at substrate concentrations well below the Km of the enzyme. The motivation for 
this work is given in in Chapter 1 while the results are presented in Chapter 3. It should be 
apparent to the reader that the motivation for this work revolved mainly around the human 
enzyme, yet the work was done entirely on the E. coli enzyme. In fact, the objective of the 
research was to develop an assay that could be applied to blood samples. However, blood 
could not be brought into the laboratory for safety reasons, and commercial supplies of 
human G6PD were expensive and would have required purification before use. Some 
thought was given to expressing the human protein in E. coli, but there was uncertainty as to 
the level of expression and the solubility of the expressed protein. Other workers in the 
laboratory had established that the E. coli enzyme expressed well and that the His-tagged 
protein was very soluble. The results obtained with the E. coli protein can use by other 
workers to develop improved assays for the human enzyme. The specific activity of the 
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human and E. coli enzymes may differ a little so that the concentrations of downstream 
enzymes may need to be adjusted to optimize the assay, but these modifications are expected 
to be relatively minor. 
The directed evolution of G6PD identified a number of changes that enhanced the stability of 
the resultant variants as described in Chapter 4. The procedures used in the evolution had 
worked, and in some senses, the process had converged in that a number of variants were 
identified with near 100% stability as determined by the screen conditions. However, the 
sequences of the variants with very high stability were quite different indicating that 
increased stability could be achieved in a number of ways. In fact, new changes were 
observed in the fourth round suggesting that many more changes could be found that 
satisfied the criteria for stability as defined by the screen. The question arose: to continue 
with directed evolution or characterize the current mutants?. At the time that this question 
was being addressed, there was also some concern as to whether there was sufficient time 
(within the confines of an Australian Ph.D.) to allow either option to be completed 
satisfactorily. Both options to the above question have merit, but it was thought that the 
characterization of a limited number of variants could be completed within the allowed time 
and, in addition to helping in the formulation of new screens, it would further our 
understanding of G6PD structure and function. This information can be found in Chapters 5 
and 6. 
Most of the results reported in Chapter 5 were expected. The variant proteins were all stable 
under the screening conditions – that has they retained activity after heat treatment at 60 oC 
for half an hour. However, there was one exception. One variant survived heat treatment at 
60 oC for a much longer time. This variant had a change that arose in the generation of the 
fourth round library. This variant (G6PD2, 2G) was clearly superior to all other variants that 
had been obtained. Given the results obtained with this mutant, it was thought that future 
evolution rounds should be carried out with a screen that involved heat treatment for an 
extended period of time so that more variants could be identified that had good temporal 
stability after heat treatment at 60 oC. A library constructed with a number of such variants 
would ensure that good temporal stability was passed on to successive generations when 
screened at temperatures higher than 60 oC.  It is also clear that, one must increase the 
temperature for screening after no apparent changes can be seen after several rounds. The 
results also suggested that it is worthwhile characterizing the stable mutants in detail to 
understand the mechanism that responsible for the stability. The variant G6PD2, 2G has a 
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Tm50 of 66 ± 2 oC, which is higher than the native human G6PD that is approximately 55 
°C.1 With the higher stability, it could potentially serve as a useful standard for G6PD in the 
field study. 
One of the unusual properties of G6PDs is their ability to adopt multiple oligomeric forms. 
For this reason, it thought that some attempt should be made to monitor possible differences 
in the oligomeric structures of variant G6PDs. However, it was not easy to find a suitable 
technique to determine the oligomeric structure. Probably the best technique would have 
involved the use of an ultracentrifuge2 or small angle X-ray scattering (SAXS)3, but no such 
instrument was available in the ANU and instruments in other Australian universities were 
heavily used and not readily available. As described in Chapter 6, the protein was cross-
linked to preserve the oligomeric structure and then run on a gel.  Although this system gave 
some indication that it could monitor some different oligomeric forms, it was clear that most 
of the protein was not cross-linked and that refinements in the experimental system were 
required. Preliminary experiments with a size exclusion column gave more promising 
results, again described in Chapter 6. It was clear that the native protein at low 
concentrations existed as an equilibrium between dimer and tetramer with a hint of a higher 
molecular weight species (shoulder peak in Figure 6.4). At the same concentrations the 
variant proteins showed little evidence of the dimer and, in some cases, showed evidence of 
much larger species that the tetramer. The human protein is reported to exist as an 
equilibrium between a dimer and tetramer4, 5 – it would be interesting to examine oligomeric 
structure at higher protein concentrations. Clearly, further studies of the native and variant 
proteins should be carried out to gain a better idea of the oligomeric forms that can be 
adopted by these proteins. From the results obtained in Chapter 6, it appears that E. coli 
G6PD can form very large oligomeric structures, however, this requires verification and 
quantitation with more sophisticated techniques. 
The G6PD2, 2G variant was somewhat unusual in that it appeared to be predominantly a 
tetramer. If other oligomeric forms were present, they were not apparent from an 
examination of the elution profile. It was felt that this variant was a good candidate for 
crystallization trials – but no crystallization conditions tested lead to useful crystals. For 
crystallization attempts, three sample conditions were tested: (i) 5 mg/mL of protein only; 
(ii) 5 mg/mL of protein with 1 mM NADP+ and (iii) 5 mg/mL of protein with 3 mM of G6P. 
The protein was dialyzed against buffer A (50 mM sodium phosphate pH 6.5) and the 
crystallization was set-up manually at 18 °C. The Hampton Research screen HT (HR2-130) 
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yielded a number of crystal forms obtained with A1, B2, B12, E12 and F8 solution. 
Systematic variation of the precipitant concentrations as well as the pH range of these 
solutions were optimized but still did not contribute any suitable crystal for diffraction. For 
future attempts, crystallization using different screening solution i.e. Index HT, Salt, and 
PEG screen and co-crystallization using NADP+ analogue like methotrexate could also be 
performed.
Another set of experiments in this category involved attempts to remove the structural 
NADP+ from the protein so that the apo-protein could be characterized. A number of 
attempts were made using methods described in the literature,6 but none resulted in a 
significant yield of the unbound protein. Unfortunately, there was not sufficient time to 
refine these experiments. It was thought that the structural NADP+ was involved in 
stabilizing the dimer. Residue changes were observed close to the structural NADP+ binding 
site, but none appeared to be close enough to abolish binding. In addition, the UV/visible 
spectra, in the region around 260 to 280 nm, of the purified variant proteins were very 
similar to that of the native protein. This suggested that NADP+ bound very tightly to the 
native and variant proteins; evolution had not dislodged this effector. 
Taken together, the results described in Chapters 5 and 6 strongly suggest that there is a 
connection between the stability and the oligomeric structure of G6PD. Further 
experimentation to deconvolute which mutations in the selected variants are responsible for 
their observed phenotypes would be important. For example, mutants G6PD2-12 and G6PD7, 
11F both form very large oligomers but do no appear to have a shared mutation between them, 
that is also absent from the other two mutants (Table 7.1). Furthermore, with more rounds of 
evolution, as described in Chapter 4, it may be possible to obtain an active and very stable 
form of G6PD that exists in a single oligomeric form. Such a variant would be of some 
commercial value and an ideal form to study the structure and function of G6PDs. 
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Appendices 
 
Appendix A: Primers  
 
Primer Oligos sequence  (5¶ - 3¶) Commentary 
 
G6PD-1 
(For) 
CGG GTG CAG CAT ATG GCG GTA ACG 
CAA ACA 
  
Gene specific primers 
G6PD-2 
(Rev) 
CGC AAG CTT GAA TTC TTA CTC AAA 
CTC AAT 
G6PD-6 
(For) 
GTG AAA GTA CTG AAG TCT CTG C 
 
Internal primer used 
for sequencing of 
pCY76 plasmid 
 
M13 
(Rev) 
GTA AAA CGA CGG CCA 
 
 
G6PD-3 
(For) 
CGG GCA TGC CATATG GCG GTA ACG 
CAA ACA GCC 
Sequencing primers 
for pETMCSIII 
G6PD-4 
(Rev) 
CCG AAGCTT CTG CAG CTC AAA CTC 
ATT CCA GGA AC 
 
 
Appendix B: Native Amino acids sequences   
 
E. coli G6PD  
 
MAVTQTAQACDLVIFGAKGDLARRKLLPSLYQLEKAGQLNPDTRIIGVGRADWDKAAYTKVVREALE
TFMKETIDEGLWDTLSARLDFCNLDVNDTAAFSRLGAMLDQKNRITINYFAMPPSTFGAICKGLGEA
KLNAKPARVVMEKPLGTSLATSQEINDQVGEYFEECQVYRIDHYLGKETVLNLLALRFANSLFVNNW
DNRTIDHVEITVAEEVGIEGRWGYFDKAGQMRDMIQNHLLQILCMIAMSPPSDLSADSIRDEKVKVL
KSLRRIDRSNVREKTVRGQYTAGFAQGKKVPGYLEEEGANKSSNTETFVAIRVDIDNWRWAGVPFYL
RTGKRLPTKCSEVVVYFKTPELNLFKESWQDLPQNKLTIRLQPDEGVDIQVLNKVPGLDHKHNLQIT
KLDLSYSETFNQTHLADAYERLLLETMRGIQALFVRRDEVEEAWKWVDSITEAWAMDNDAPKPYQAG
TWGPVASVAMITRDGRSWNEF 
 
Zm6PGL 
 
MPIVLNVWQVSMEKKMTEAEWWEFENVEAMAKQIADDIEFIIKQAIEKKGRALIIVPGGSTPKLVF
PTLAARDLDWSKVTLMLTDDRLVAKDNPLSNFGLLTKHFGSSGAELVSLIDENYLDDRAAAGRAAD
QKLASYKWPADLVWLGMGNDGHTASIFPGPNFDEAVNGPRERRALGLLPVPLPPEAPVARVTLSLS
TLASAHTVMVVITGDHKRTVLTDALKEGASSRLPVGRVLGET EASIDVYWSK* 
 
E. coli 6PGD 
 
MSKQQIGVVGMAVMGRNLALNIESRGYTVSIFNRSREKTEEVIAENPGKKLVPYYTVKEFVESLET
PRRILLMVKAGAGTDAAIDSLKPYLDKGDIIIDGGNTFFQDTIRRNRELSAEGFNFIGTGVSGGEE
GALKGPSIMPGGQKEAYELVAPILTKIAAVAEDGEPCVTYIGADGAGHYVKMVHNGIEYGDMQLIA
EAYSLLKGGLNLTNEELAQTFTEWNNGELSSYLIDITKDIFTKKDEDGNYLVDVILDEAANKGTGK
WTSQSALDLGEPLSLITESVFARYISSLKDQRVAASKVLSGPQAQPAGDKAEFIEKVRRALYLGKI
VSYAQGFSQLRAASEEYNWDLNYGEIAKIFRAGCIIRAQFLQKITDAYAENPQIANLLLAPYFKQI
ADDYQQALRDVVAYAVQNGIPVPTFSAAVAYYDSYRAAVLPANLIQAQRDYFGAHTYKRIDKEGVF
HTEWLD* 
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